Review

Nanomedicine strategies for management of drug resistance in lung cancer

Mohamed Haider 1*, Amr Elsherbeny 2, Valeria Pittalà 3, Antonino N. Fallica 3, Maha Ali Alghamdi 4,5, Zahid Hussain 1, Ghalia Khoder 1 and Khaled Greish 5

1 Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, University of Sharjah, Sharjah 27272, UAE; mhaider@sharjah.ac.ae; zhussain@sharjah.ac.ae; gkhoder@sharjah.ac.ae
2 Division of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK; amr.elsherbeny@nottingham.ac.uk
3 Department of Drug and Health Science, University of Catania, Catania 95125, Italy; vpittal@unicct.it; antonio.fallica93@gmail.com
4 Department of Biotechnology, College of science, Taif University, Taif 21974, KSA; mahaasg@agu.edu.bh
5 Department of Molecular Medicine, Princess Al-Jawhara Centre for Molecular Medicine, School of Medical Sciences Arabian Gulf University, Manama 329, Bahrain; khaledfg@agu.edu.bh

*Correspondence: MH: mhaider@sharjah.ac.ae; Tel.: +971567615401

Abstract: Lung cancer (LC) is one of the leading causes of cancer occurrence and mortality worldwide. Treatment of patients with advanced and metastatic LC presents a significant challenge as malignant cells use different mechanisms to resist chemotherapy. Drug resistance (DR) is a complex process that occurs due to a variety of genetic and acquired factors. Identifying the mechanisms underlying DR in LC patients and possible therapeutic alternatives for more efficient therapy is a central goal of LC research. Advances in nanotechnology resulted in the development of targeted and multifunctional nanoscale drug constructs. The possible modulation of the components of nanomedicine, their surface functionalization, and encapsulation of various active therapeutics provide promising tools to bypass crucial biological barriers. These attributes enhance the delivery of multiple therapeutic agents directly to the tumor microenvironment (TME), resulting in reversal of LC resistance to anticancer treatment. This review provides a broad framework for understanding the different molecular mechanisms of DR in lung cancer; presents novel nanomedicine therapeutics aimed to improve the efficacy of treatment of various forms of resistant LC; outlines current challenges in using nanotechnology for reversing DR; and discusses the future directions for clinical application of nanomedicine in management of LC resistance.

Keywords: Nanomedicine; drug resistance; lung cancer; chemotherapeutic agents; drug delivery

1. Introduction

Lung cancer (LC) is recognized as the second most diagnosed type of cancer and the leading cause of cancer-related deaths globally [1]. According to the World Health Organization, 2.21 million cases of LC were reported in 2020 worldwide [2]. LC is classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The pace of treatment of SCLC is mainly faster than NSCLC because of the ability of the tumors to spread quickly. NSCLC is less aggressive, but it is generally identified at the advanced stages. Around 80% of LCs are NSCLC, and they can be further subdivided into adenocarcinomas, squamous cell, bronchioalveolar, and large cell carcinoma. The remaining 20% of LCs show proper ties of neuroendocrine differentiation [3]. The current approaches for management of LC involve surgical removal of non-metastatic tumors, radiation, and chemotherapy. Chemotherapeutic agents inhibit rapidly dividing cancer cells but also affect normal cells with high proliferation rate (e.g., bone marrow, hair follicle, etc.) resulting in undesirable side effects that may require dose reduction or discontinuance of the
therapy. This unfavorable outcome is mostly due to poor and random delivery of those agents [4].

In addition, the therapeutic effectiveness of chemotherapeutic agents is limited due to the development of DR in cancer cells [5]. Cancer DR is the ability of the tumor cells to develop a certain mechanism to overcome and resist the cytotoxic or inhibitory effect of the chemotherapeutic agent, and therefore reduce the effectiveness of chemotherapy [6]. Currently, the failure of chemotherapy due to DR account for 90% of clinical metastasis cases [6]. To overcome DR, chemotherapeutic agents need to be administered at larger doses with higher frequency which in turn may result in increased toxicity and lower patient survival rate. Alternatively, combination of two or more chemotherapeutic agents may be administered to achieve synergistic effect and reduce the rate of DR [7]. This approach has improved the effectiveness of chemotherapy but has not yet eliminated the side effect associated with non-specific uptake by normal cells.

The need for an alternative strategy to deliver chemotherapeutic agents to be relatively more selective in targeting malignant cells and overcome drug resistance has been the main focus of recent studies. Over the last two decades, nanotechnology has played a major role in delivery of medicinal agents to overcome the obstacles of the conventional therapy [8,9]. A range of different types of nanocarriers (1 to 500 nm) have been developed for the delivery of drug molecules, nucleic acid and diagnostic agents [10–15].

The use of nanoparticles (NPs) as carriers for chemotherapeutic agents has significantly improved their effectiveness, safety, stability and pharmacokinetic profile [9,12,16]. Biocompatible nanocarriers can be tailored to suit the pathophysiology of the tumors, enhance the physicochemical properties of the drug and its permeability and retention time due to their unique sizes and possible surface modifications [12,14,16,17]. Furthermore, improvement in drug targeting by encapsulation in suitable NPs reduces the adverse effects associated with chemotherapy as normal cells are protected from the cytotoxic effect of the anticancer drugs [12,16,18].

In this review, we present the different molecular mechanisms of DR in LC and discuss the use of several types of nanocarriers to improve the chemotherapeutic outcome after treatment of drug resistant LC with anticancer drugs. We also outline the current challenges in using nanotechnology for reversing DR and discuss possible directions for future research.

2. Nanomedicine applications in management of lung cancer drug resistance

2.1. Tumor Microenvironment

Cancer cells can control and influence the function of their environment by releasing a complex signaling networks for their own benefits. Thus, cancer cells exist in a dynamic interaction with their surrounding environment that consists of cells and non-cell components which allows them to evolve and grow resulting in cancer progression, metastasis, and DR (Figure 1) [19]. TME includes stromal cells which mainly consist of tumor epithelial cells, cancer-associated fibroblast (CAFs) as well as immune cells. Non-cellular factors include extracellular matrix (ECM) components such as growth factors, degradation enzymes and inflammatory mediators. It also includes exosomes and apoptotic bodies in which they are known as an extracellular vehicle (EVs). Moreover, TME has special unique features including hypoxia and acidic environment [20–22]. The lung TME plays an imminent role in cancer cell resistance by interfering with the pharmacokinetic distribution of the anti-cancer agent [23]. The uncontrolled angiogenic activity, dense desmoplastic stromal layer, and abnormal interstitial and oncogenic pressures compromises the activity of the chemotherapeutics in inducing their cytotoxic activity [24]. In addition, the cross-talk between tumor and stromal cells modulates the response to these agents and reduces their potential within the microenvironment [25]. Poor immune cell infiltration
and activation induced by the harsh conditions surrounding the tumor cells is also of great importance to tumor proliferation and metastasis [26]. These barriers lead to a decline in intracellular accumulation of the anticancer agents, an increase in tumor-acquired resistance and poorer clinical outcomes.

Figure 1. Representation of cellular components of TME in LC

NPs have long been sought to overcome the limitations associated with the unique tumor setting within LC (Table 1) [23,27,28]. Given their inherent passive targeting enhanced permeation and retention (EPR) properties alongside their ability to be actively formulated to utilize the internal factors regulating the TME, NPs may well improve the clinical response to the therapy in question [29]. Recent studies outlined how novel nano delivery systems could be prepared to exploit current TME hindrances in LC, such as the acidic nature of the microenvironment, increased accumulation of reactive oxygen species (ROS), expression of unique antigens at the tumor site, activation of immunogenic tissue as an immunomodulatory therapy, or external stimuli triggered drug release, amongst others, achieving a relatively higher targeted activity on the tumor cell compared to the conventional therapy [30–34].

In a study by Yu-Lun Lo et al., a pH/redox-responsive micelle based on poly(ε-caprolactone)-SS-poly (methacrylic acid) (PCL-SS-PMAA) diblock copolymer was fabricated for dual drug delivery of paclitaxel (PTX) and cisplatin (CIS). The NPs were intended to utilize the acidic/ROS rich TME for selective release of the chemotherapeutic agents whilst enhancing their intracellular accumulation. In vitro release studies revealed that the co-loaded formulation released almost 100% of its anticancer agents after 192 h when subjected to an acidic reducing environment (pH 5.5 + Dithiothreitol (DTT)) compared to only 40 % of the chemotherapeutic agents released at normal conditions (pH 7.4 with no DTT). This suggests that these NPs can maintain their integrity until exposed to the TME, incurring selective drug release. Cell apoptosis studies also revealed that treatment of NCI-H520 LC cells with the dual loaded PTX/CIS cross-linked micelles resulted in a 1.77-fold increase in cell death compared to the free drugs [35]. Similarly, redox-responsive manganese dioxide NPs (MnO2 NPs) stabilized with biocompatible polymers polyvinylpyrrolidone (PVP) and polyacrylic acid (PAA) were synthesized and analyzed using magnetic resonance (MR) imaging and measurement of cytotoxic activity on gefitinib-resistant LC cell lines. MnO2 NPs showed glutathione (GSH)-responsive dissolution and subsequent enhancement in MR imaging. In addition, the NPs induced a significant selective cytotoxic effect on NSCLC cells upon X-ray irradiation without a noticeable damage to normal. Therapeutic efficacy was also achieved when the cells were treated with MnO2 NPs in hypoxic conditions [36]. It would be quite interesting to see these particles applied on 3D-co cultures, organoids, or in vivo and the results compared to current
therapeutic regimens; to mimic, to a greater extent, the potential selectivity of these particles.

In a different study, PTX was loaded in N-succinyl-palmitoyl-chitosan acid responsive micelles decorated with cRGDyK peptide to inhibit NSCLC. cRGDyK peptide is an integrin ligand analogue that can target tumors via specific binding integrin receptor overexpressed in the tumor neo vasculature but poorly expressed on resting endothelial cells and most normal organs. The authors suggested that these particles were acid responsive since the drug release at pH 5.3 was almost 20% higher than at pH 7.4 (65% and 45%, respectively after 72 h). While this statement is true to an extent, it lacks accuracy since results were comparable at both pH settings. A more comprehensive approach could have been achieved had the authors compared the time required for all the encapsulated drug to be released from the nanocarriers at both pH conditions. Nevertheless, when looking at the cytotoxicity of the functionalized micelle on A549 human NSCLC, the IC50 was 5x and 4x lower when compared to Taxol formulation and unfunctionalized formula, respectively. This suggests that the cRGDyK peptide may well increase cellular uptake into the tumor tissue. The authors further supported their claim by studying the tumor uptake properties on tumor-bearing mice after 24 h. The ex vivo images of excised organs revealed that the accumulation of cRGDyK functionalized micelles in the lungs was more remarkable than that of unfunctionalized micelles. In vivo anti-tumor activity showed a significantly lower tumor mass in mice treated with PTX/cRGDyK-SPCS micelles than those treated with Taxol® and PTX/SPCS micelles, henceforth indicating that the functionalized drug-loaded micelles possessed the strongest inhibitory efficiency on the tumor [37].

Enhancing the immunotherapeutic outcome of current immunotherapy using NPs in LC has also been explored through the preparation of a combinatorial chemotherapy/immunotherapy Polo-like kinase 1 (PLK1) inhibitor (Volasertib) – loaded mesoporous silica NPs decorated with PD-L1 antibody. PLK1 is an important mitotic kinase that is overexpressed in LC promoting oncogenesis and tumor metastasis. PD-L1 expression on tumor cells inhibits tumor-directed cytotoxic CD8+ T cell activity by binding to PD-1 receptor on T cells and suppressing their function. Hence, a combinatorial delivery system is for co-delivery of PLK1 inhibitor and PD-L1 antibody is thought to selectively kill tumor cells whilst upregulating PD-L1 expression in surviving cancer cells and/or increasing density of tumor infiltrating lymphocytes providing an opportunity to achieve a targeted therapeutic activity in a positive feedback manner. The NPs-based immunotherapy showed a significant reduction in the effective doses of volasertib and PD-L1 antibody by 5-fold in a metastatic lung in vivo tumor model by actively mediating CD8+ T cells allowing the immune cells to induce their cytotoxic activity on the cancer cells. These results clearly demonstrate the influence of targeting the TME on improving the clinical outcomes of current therapy [38]. Accordingly, exploiting the molecular pathways and interactions which govern the TME could potentially enhance the current approach to therapy using novel nano drug delivery systems (DDS).

2.2. Multidrug resistance

Tumor multidrug resistance (MDR) remains a major obstacle that continues to hinder the effective progression of current curative cancer therapy in LC [39]. Innate and acquired phenotypes have been frequently identified as major cancer cell defense mechanisms following exposure to chemotherapeutic regimens [40]. Until now, several MDR mechanisms have been increasingly linked to members of the ATP-binding cassette (ABC) membrane pumps with 48 identified genes [41]. A number of these efflux transporters including P-glycoprotein (P-gp; ABCB1; MDR1), breast cancer resistance protein (BCRP; ABCG2) and MDR-associated protein 1 (MRP1; ABCC1), have been greatly recognized in reducing the efficacy of anti-cancer agents in tumor cells through a noticeable decrease in their intracellular accumulation in an ATP dependent manner (Figure 2) [42]. Commonly used chemotherapeutic agents including taxanes, platinum compounds, and gemcitabine fall victim to these pathways [43–46].
Other non-ABC drug transporters in LC such as lung resistance protein (LRP) have shown their ability in reducing the biodistribution of anti-cancer agents at the tumor microenvironment; reducing the overall efficacy of the medication regimen [41,47]. In a study which examined the mortality rate of patients expressing MDR and LRP transporters in NSCLC, survival rates were greatly diminished upon overly expression of these efflux transporters when compared to pump-free tumors; recognizing their imminent role in the chemoresistance of the disease [48]. Drug transporter-independent mechanisms also play a prominent role in the development of MDR in LC. An important superfamily of antiapoptotic proteins known as the B-cell lymphoma (Bcl-2) appear to be upregulated in LC; promoting cytotoxic resistance through the dysregulation of apoptosis in tumor cells [49–51]. In addition, mutations in the p-53 transcriptional factors which regulate the expression of numerous genetic material has brought about considerable MDR in LC [52–54]. Thus, there is a substantial need for the development of novel systems to overcome MDR shortcomings of current chemotherapy.

Recent studies have explored the potential role of nano DDS in overcoming several MDR processes in in vitro and in vivo studies on LC. It was suggested that anticancer drug-loaded NPs can evade efflux transporters due to the ability of NPs to enter the cells in large amounts by endocytosis rather than diffusion, then release the drug inside the cell at a perinuclear site away from the efflux pumps [55]. Another strategy involves using nanocarriers for co-delivery of P-gp inhibitor and chemotherapeutic agent. In a study by Liang Xu et al. doxorubicin (DOX) was co-loaded with cyclosporin as a P-gp inhibitor in a poly (lactic-co-glycolic acid) PLGA-based nano vectors and applied on PTX-resistant A549 cell line (A549-TAXOL). The co-loaded formulation showed a significant decrease in cellular viability after 72 h relative to free DOX and DOX-loaded NPs. These results suggest the significance of P-gp inhibition on achieving chemosensitization and improving cellular cytotoxicity outcomes. In vivo studies on A549-TAXOL xenografts subcutaneously injected to Female BALB/c nude mice also revealed a significantly lower tumor volume with the co-loaded formulation relative to the free drug [56,57].

Similarly, when a photosensitizer, 5,10,15,20-Tetrakis(4-hydroxy-phenyl)-21H,23H-porphine (pTHPP) was loaded into PLGA-lipid hybrid NPs, the IC50 of the NPs were 523x and 45.2x lower than etoposide and PTX, respectively, on etoposide resistant A549 cell lines (A549RT-etos). Treatment with free pTHPP in the presence or absence of light irradiation did not produce any cytotoxic effects in both A549 and A549RT-etos cells due to its very poor solubility and inability to be uptaken into the cells. The hybrid NPs enhanced the solubility of the free agent and achieved a higher cytotoxic effect when compared to conventional chemotherapy. Similar results were also obtained when the optimum NPs were used on detachment induced MDR acquired by A549 cells cultured as floating cells under non-adherent conditions mimicking metastasizing cancer cells in the
blood/lymphatic circulation. Whilst these results are very promising, having cells been cultured in a 2D monolayer may overestimate the potential of these particles. Further studies on 3D co-culture models and/or in vivo assays may more closely resemble clinical outcomes [58].

In a different study, functionalized PTX-liposomes with d-α-tocopheryl polyethylene glycol 1000 succinate-triphenylphosphine conjugate (TPGS1000-TPP) as a mitochondrial targeting molecule and P-gp inhibitor were prepared and tested on drug-resistant human LC cells A549/cDDP cells. The targeted liposomal particles had a size of 80 nm and an encapsulation efficiency >85%. They demonstrated almost 40% increase in cytotoxicity compared to the free chemotherapeutic agent. In addition, the % apoptosis rate was 4% higher on resistant cell lines relative to PTX alone. Further studies revealed that the targeting PTX liposomes significantly enhanced the cellular uptake initiating a cascade of caspase 9 and 3 reactions, henceforth activating the pro-apoptotic Bax and Bid proteins and suppressing the anti-apoptotic Bcl-2 protein, thereby enhancing the apoptosis by acting on the mitochondrial signaling pathways. In vivo studies on A549/cDDP xenografts subcutaneously injected to Female BALB/c nude mice revealed a 37% increase in tumor volume inhibitory rate in the targeting PTX liposomes over the free drug suggesting the ability of the DDS to overcome MDR pathways. However, it is important to note that the drug-free formulation showed a 30% cytotoxicity effect which raises the concern of whether these particles could inherently be cytotoxic on normal cells which requires further investigation [59].

The use of NPs to overcome other MDR pathways in LC by encapsulating genetic materials has also been explored. It was suggested that NPs inhibit the expression and function of efflux transporters by targeting microRNAs (miRNA) which are special non-coding RNA that play an important role in protein expression and cellular transfection [60]. Shuting Ma et al. co-loaded survivin siRNA and a tetravalent platinum complex of cisplatin (Pt (IV)) prodrug in a protamine/hyaluronic acid nanocarrier coated with polyglutamic acid (PGA) for the treatment of platinum-resistant LC. Survivin is a cancer biomarker and a member of the anti-apoptosis family which has been found to be overly expressed in drug-resistant tumor cells. Silencing this pathway using siRNA was investigated in this study to observe its relative efficacy in overcoming CIS transporter independent MDR pathways. Survivin siRNA was loaded into a NPs to overcome its poor biodistribution in vivo and achieve increased intracellular accumulation. Cytotoxicity results on 2D A549/cDDP cell lines after 24 h revealed a slight increase in % apoptosis in the co-loaded formulation relative to CIS. This unexpected poor outcome drove the researcher for further investigation since the drug release from the NP formulation was achieved after 191 h (97.3% for pH 5.0, 29.7% for pH 6.5). Western blot analysis showed that the amount of survivin protein expression of NP-siRNA/Pt (IV) was higher than that of the survivin siRNA due to the incomplete in-vitro release of survivin siRNA from the NP after 24 h. In vivo performed on A549/DDP tumor-bearing nude mice showed that treatment with the co-encapsulated formulation resulted in highest tumor inhibition rates (82.46%) compared to free CIS (62.52%) after 14 days of treatment. Hence, despite the poor 2D cellular outcomes, in vivo models demonstrated higher efficacy with the dual loaded formulation highlighting the importance of in vivo models in exploring the potential of these formulations. However, it would have been interesting to also compare these results to free siRNA in vitro and in vivo to visualize the importance of loading such entities in NPs over the free agents [61].

A self-assembled polyjuglanin NPs loaded with DOX and anti-Kras siRNA was also formulated for attenuating MDR in human LC. Down-regulation of the Kras gene by siRNA has previously caused defective abilities of proliferation, clonal formation, migration, and invasion of cancer cells. In vitro studies were carried out using DOX-resistant A549/DOX and CIS-resistant H69/CIS human LC cell lines to investigate the effects of the NPs on MDR. The results showed that the combination therapy achieved a higher in vitro cytotoxicity result on both cell lines by Oncogene dose-dependently reducing Kras, P-gp, and c-Myc, expression, whilst improving p53 genetic modulation in drug-resistant cells.
These results were further supported by in vivo studies where the NPs formulation achieved reduced tumor growth compared to the free DOX, accompanied with reduced KI-67 and enhanced TUNEL positive levels in drug-resistant xenografted BALB/C nude mice [62]. In such, NPs clearly demonstrate their versatility in loading diverse agents and achieve MDR reversal by overcoming multiple molecular pathways in LC outlining their potential in enhancing the therapeutic actions of current and future regimens.

2.3. Cancer Stem Cells

Currently it is well accepted that a subpopulation of LC cells residing within the tumor tissue exhibits unique biological phenotypes and characteristics with stem cell capacities including lineage differentiation and self-renewal [63]. In addition, they can further undergo invasion, metastasis, tumorigenesis, chemoresistance, tumor relapse, and escape immune surveillance, henceforth are referred to as Cancer Stem Cells (CSCs) [64]. Studies have shown the vital role CSCs play in the occurrence and development of LC tissue outlining their significance in mediating all cancer hallmarks. Recent studies suggest that the “stemness” of tumor cells may be caused by genetic mutations to specific genes including TP53; or acquired through the activity of the cancer microenvironment substances such as interleukins, nitric oxide, or hypoxic conditions. This situates the CSCs within a setting rich with external signals such as cytokines, growth factors, extracellular matrix, and other physicochemical factors and surrounded by variety of cells such as immune cells, stromal cells, endothelial and perivascular cells [63–67]. Several biomarkers have already been identified within LC including ALDH1, CD133, CD44, CD166, CD20, and others [65]. Understanding the CSC environment may well provide effective therapeutic strategies to overcome the aforementioned barriers; in such achieving an improved therapeutic outcome and a lower rate of tumor recurrence.

The use of NPs to selectively target the overexpressed biomarkers and improve the therapeutic activity of cytotoxic agents on CSCs has been explored. Hyaluronic acid functionalized/ all-trans-retinoic acid (ATRA) loaded albumin-based cationic NPs were prepared and evaluated on CD44 overexpressed CSCs in in vivo lung metastasized tumor models. Pharmacokinetic biodistributions revealed a selective uptake of the HA-decorated NPs in the tumor tissue of the mouse with a significant reduction in tumor growth relative to the pristine drug [68]. Similarly, Dandan Liu et al. formulated a heat Shock protein Inhibitor-loaded silica-coated Fe3O4 magnetic NPs decorated with anti-CD20 CSCs specific antibodies to kill both cancer cells and CSCs. The multifunctional thermoresponsive/ immunomodulant/ chemotherapeutic NPs demonstrated almost 98% eradication of human lung CSCs within 30 min of external application of alternating magnetic field (AMF). Further in vivo studies revealed that the combinatorial therapy significantly suppressed tumor growth and metastasis in lung CSC xenograft-bearing mice, demonstrating a relatively high efficacy whilst maintaining good biocompatibility and targeting capability [69]. This illustrated that such NPs could effectively serve as a platform for further exploration on selective antitumor activity on normal cancer cells and CSCs alike.

Epithelial-mesenchymal transition (EMT) is another crucial process involved in promoting cancer invasion and metastasis [70]. Cancer cells undergoing EMT show similar characteristics to CSCs such as increased chemoresistance and oncogenic activity whilst entering a period of dormancy upon EMT completion. Therefore, it can be safely concluded that EMT could be amongst the contributing factors in inducing and generating the CSCs and their niche within the TME [71]. Accordingly, interfering with the EMT pathway is likely to halt the process of CSC development and promote effective therapeutic outcomes. In a study by Chio et al., miR145 was loaded into polyurethane-short branch-polyethyleneimine (PU-PEI) NPs and delivered into lung adenocarcinoma CSCs (LAC-CSCs). Tumor growth and metastasis appeared to be reduced upon delivery of the loaded carrier systems in in vivo studies to xenograft tumors. In addition, xenografts appeared to be more sensitive to chemoradiotherapies prolonging the survival times of tumor-bearing mice [72]. Another important regulator of signaling pathways associated
with CSCs is the SOX2 gene [73]. Andey et al. prepared a cationic lipoplex for the targeted delivery of SOX2 small interfering RNA (CL-siSOX2) to SOX2-enriched, CSC-derived orthotopic and xenograft lung tumors in CB-17 SCID mice. The authors presented well-established work which demonstrate the significance of CL-siSOX2 in inhibiting the expression of stemness markers in xenograft tumors including SOX2, NANOG, c-MYC, and KLF4. These lipoplexes also reduced tumor volume in mice, suggesting that such effects were attributed to the crucial role of SOX2 in the regulation of signaling pathways associated with CSCs [74]. The results of these studies show the potential of NPs as effective carriers for a range of therapeutic modalities; improving their relative selectivity and overcoming the limitations associated with CSCs in the lung tissue.

2.4. Metabolic inactivation of the anticancer drugs

Drug detoxification is considered a key resistance mechanism in several types of malignant tumors (Figure 3). Each population of cancer cells can respond differently to anticancer drugs due to the associated genomic variation [75]. The metabolism of chemotherapeutic agents can progress intracellularly and/or extracellularly eventually affecting the overall efficacy of the given anticancer agent [76].

![Figure 3. Different mechanisms of DR in LC](image)

The metabolism of anticancer drugs in the body involves two phases. In the initial phase, cytochrome-P450 (CYP-P450) enzymes may act on the functional groups of the anticancer drugs and modify them by oxidation, reduction, or hydrolysis reactions. Examples of functional groups include hydroxyl (-OH), amino (-NH2), and carboxylic acid (-COOH). The second phase involves further modification of those altered functional groups by glucuronidation, sulfonation, and conjugation of amino acid creating more hydrophilic and polar drug metabolites that are readily excreted [77]. Metabolism may also involve methylation and acetylation reactions which could terminate the activity of the drugs. These conjugation reactions normally occur in specialized cells in the liver to protect the host from the toxicity of anticancer drugs [78–80]. However, similar pathways have been demonstrated at the tumor site in many types of cancer including LC [80]. Augmented metabolic activation in cancer cells can eventually influence the pharmacokinetics and/or pharmacodynamics of anticancer drugs [81,82].

For anticancer prodrugs such as cyclophosphamide, the concentration of the active drug molecules at the tumor site is dependent on the metabolism of the prodrug and hence the metabolic activity can be a limiting factor for the effectiveness of the treatment.
The overproduction of specific enzymes at tumor sites can be used to render a prodrug into cytotoxic metabolites strictly at those sites [83]. Many studies have exploited this phenomenon in delivering nano-based chemotherapeutics such as using HPMA enzyme-linked systems that are specifically cleaved by tumor specific enzymes such as cathepsin B [84].

Furthermore, there are many examples of ongoing research utilizing key metabolic pathways in overcoming anticancer DR. For instance, the glutathione detoxification pathway is a system used by the cells to maintain an intrinsic homeostatic state. It plays an essential role in detoxification of the peroxides that are generated from oxygen radicals as result of treatment with anticancer drugs [85]. It consists of glutathione (L-glutamyl-L-cysteinyl-glycine, GSH), related enzymes, and glutathione S-conjugate complex export protein (GS-X pump). The glutathione can form a conjugate with xenobiotics, drugs, and the sulfhydryl groups of several proteins which is then catalyzed by the enzyme glutathione S-Transferases (GSTDs) and effluxed from the cells via the adenosine triphosphate dependent GS-X pump [85,86]. The significance of this system in the anticancer resistance varies according to the type of cancer cells and the difference in the levels of enzymes related to the detoxification process. In some cases, an increased level of the enzyme is involved in the synthesis of glutathione γ glutamyl cysteine synthetase (γ GCS), and the GSTDs conjugation enzyme, which are the key functional enzymes for resistance. The GST family GST, also known as MAPEG proteins, are a large superfamily found in cytosolic, mitochondrial, and microsomal [87,88]. Theses enzymes can increase the cancer cells resistance directly by the detoxification of anti-cancer drugs or indirectly via the mitogen-activated protein kinase pathway (MAPK) inhibition within RAS/MAPK signaling pathway in the cells which was reported to be present in higher levels in lung tumors than the normal bronchioles and alveoli [89,90] (17, 18).

Platinum-based compounds such as CIS are commonly used in the treatment of patients with advanced stages of LC. When the drug reaches the cancer cells it causes an increased level of ROS and DNA damage leading to cell apoptosis[91–93]. The resistance to LC congruently develops by inactivating the platinum drugs via many resistance mechanisms including the increase in the DNA repair, reduction in cellular uptake and anti-apoptosis. Several studies on the glutathione metabolic system showed that the active SH-group on glutathione can bind to the platinum-based drugs and negate their DNA targeting due to their high affinity to the anticancer drugs. With the elevated level of glutathione in the cells, the drug efflux by the GS-X pump is further enhanced and the cells become CIS-resistant [94–96].

Cancer cells display a high level of protein expression of GST and γ GCS often seen in the CIS-resistant lung as shown in several studies Table 1. This increase may be explained as an attempt to detoxify the drug. However, the internalized drugs that are conjugated to GSH can inhibit MAPK kinase pathway, which works on killing tumor cells via activation of the JNK/MAPK pathway leading to apoptosis. Therefore, this pathway is inhibited in the resistant LC cells by increased GST expression [94]. In addition to overexpression of GSH, cancer cells develop resistance to chemotherapy by the overproduction of superoxide dismutase SOD or/sulfur-containing macromolecules like metallothioneins (MTs). MTs were found in high levels in the resistant NSCLC with squamous cell lung carcinoma and adenocarcinoma. They are intracellular proteins with high content of cysteine that acts as precursors for GSH synthesis [97–99]. The concentration of GSH in the extracellular fluids of the resistance cancer cells is 100-1000 times higher than the sensitive cancer cells. In this aspect, such significant differences can be useful in drug delivery to resistant LC cells as the drug release can be enhanced through GSH-dependent thiolysis [100,101]. Accordingly, several studies reported the synthesis of nanocarriers with reducible linkers such as thioether bonds [101], disulfide bonds [102,103], and di-selenide bonds [104] that release the drug in presence of GSH. The most common and simplest bond addressed in this regard is the disulfide bond that can be inserted into polymeric micelles nano delivery systems as part of a linker between two blocks of polymers. Upon internalization by the polymeric micelles by resistant cancer cells with high levels of GSH, the
linker disulfide bond is cleaved leading to disassembly of the micelles and release of the drug [105–112]. Wang et al. synthesized polymeric micelles composed of PEG, polyethyleneimine (PEI) blocks and ATP-depleting Pluronic P123 bound together with disulfide bond and loaded with PTX and siRNA targeting polo-like kinase1 (PLKI) that acts in downregulation of ATP and interferes with the cancer cell metabolism. The results showed an increase in PTX and siRNA release accompanied by a reduction in drug efflux by fast ATP-depletion of the resistant cancer cells [113]. Similar results were obtained for NPs loaded with thiolated anticancer drugs. For example, dendrimer-encapsulated gold NPs loaded with thiolated anticancer drugs showed the same GSH-dependent enhanced drug release [114].

2.5. Inhibition of the cell death

Among the many mechanisms put in act by cancerous cells in chemoresistance is indeed the evasion of apoptosis program (Figure 3). Apoptosis, also known as type I cell death, is a regulated cell death (RCD) characterized by alterations in cell morphology, shrinkage of cytoplasm, plasma membrane blebbing and chromatin condensation which result in the formation of small vesicles, known as apoptotic bodies [115,116]. It is well known that dysregulated apoptosis in cancer cells promotes resistance to anticancer drugs [117,118].

Apoptosis consists of two distinct pathways: intrinsic and extrinsic. Stress stimuli as DNA damage initiate the intrinsic apoptotic pathway and trigger mitochondrial outer membrane permeabilization (MOMP), which eventually promotes activation of caspase-9. In turn, caspase-9 activates the caspases-3, -6, and -7 responsible for apoptosis execution. On the other hand, extrinsic apoptotic process starts with binding of specific ligands to cell surface death receptors activating caspase-8 and subsequently the other executioner caspases [118]. Cancer cells escape apoptosis program exploiting several mechanisms which not only results in primary tumor progression and metastasis but also abrogation of therapeutic response to chemotherapy [119].

Gene mutations has been observed to be one of the many factors implicated in apoptosis evasion by cancer cells. It involves the generation of abnormal transcription products leading to a loss or gain of function for several proteins, dysregulation of cellular homeostasis and resistance to apoptosis. Examples of gain function mutations are represented by catalytic subunit of PI3K (PI3KCA) mutations (E542K, E545K and H1047K) that cause sustained PI3K pathway activation. Instead, loss function mutations can occur at the expenses of BAX, p53 and Phosphatase Tensin Homolog (PTEN) genes [120–123].

The modulation of extrinsic and intrinsic apoptotic signals effects can be reconducted to a family of structurally distinct inhibitor of apoptosis proteins (IAPs): cellular (cIAP1, cIAP2), surviving, X-linked (XIAP), neuronal (NIAP), livin, Bir-ubiquitin conjugating enzyme (BRUCE), testis specific (Ts-IAP). IAPs expression in specifically upregulated during diseases progression and DR onset. Thus, the interest towards IAPs as potential targets for resistant cancer treatment [124,125]. For instance, X-linked IAP (XIAP) is upregulated in LC cells and enhance apoptosis inhibition.

Many studies have focused on finding the possible correlation between usefulness of Bcl2 family proteins and chemotherapy outcomes to make plausible predictions. A correlation between Bcl2 expression and response to chemotherapy was established in patients with LC [126,127]. However, none of the investigated apoptosis-related proteins (Bcl2, Bax, Bcl-xl, Bag1, FAS, FASL) could be helpful in predicting response to drug treatment for breast cancer[128]. Interestingly, this observation was also confirmed in other studies involving vinorelbine and docetaxel combined treatment in patients with NSCLC [129]. Thus, the rising conflict in literature which to date does not allow scientists to establish any direct connection between disrupted apoptotic pathways and chemotherapy failure.

Several approaches have been exploited to date on the use of pro-apoptotic NPs as potential chemoresistance therapy in human LC. For instance, a novel pro-apoptotic drug-drug conjugate was obtained by Shim and co-workers through the conjugation of the pro-apoptotic peptide drug (SMAC; Ala-Val-Pro-Ile-Ala-Gln, AVPIAQ) and cathepsin B-
cleavable peptide (Phe-Arg-Arg-Gly, FRRG) to DOX, resulting in SMAC-FRRG-DOX that self-assembled into NPs. Upon cellular uptake, the NPs were cleaved to obtain pro-apoptotic SMAC and cytotoxic DOX specifically in cancer cells that overexpress cathepsin B, inducing a synergic effect of the combined molecules in a metastatic LC model [130].

Wang et al. designed and synthesized a TPP-Pluronic F127-hyaluronic acid (HA) (TPH), with a mitochondria-targeting triphenylphosphine (TPP) head by formation of an ester bond. PTX-loaded TPH (TPH/PTX) nanomicelles showed great physical properties and efficacy in A549 resistant cells. TPH/PTX initiated MOMP through inhibition of antiapoptotic Bcl-2, leading to the activation of caspase-3 and caspase-9. This study was able to demonstrate the actual perks of targeting mitochondria of cancer cells to counteract and prevent DR as well as the ability of nanomicelles to enhance mitochondrial specific delivery [131–133].

Furthermore, gene therapy involving re-establishing pro-apoptotic response using NPs-based technologies for delivery has been the focus of many studies. The transfection of p53 gene by cationic solid lipid NPs (SLN) and PLGA in LC cells has been reported. The cationic SLNs were prepared by the melt homogenization method and then formulated by mixing tricaprin (TC) as a core, 3beta [N-(N', N'-dimethylaminoethane) carbamoyl] cholesterol (DC-Chol), dioleoylphosphatidylethanolamine (DOPE) and Tween 80 in various ratios. Treatment exhibited an efficient re-establishment of wild-type p53 function restoring the apoptotic program in NSCLC [134,135].

2.6. Alteration of drug targets

Resistance to chemotherapeutic agents can be due to alteration in their targets at the tumor sites. These changes occur due to molecular modifications that may begin by mutation in DNA and alterations in protein expression resulting in a decrease in the affinity the drugs to their binding targets and DR (Figure 3). For example, treatment of SCLC with DOX in combination with platinum drugs inhibit the topoisomerase enzymes in the cells by intercalation between the DNA bases causing inhibition to the enzyme gyrase that is responsible unwind the structure of DNA during the DNA replication and ultimately causing DNA breakage. Many of resistant cancer cells can survive this treatment by modifying topoisomerase II gene expression and hence altering the target of DOX [75,136].

Similar DR mechanism was also reported for anticancer drugs that target specific signaling kinases such as the epidermal growth factor receptor (EGFR) family [24,137,138]. In this case, a mutation commonly occurs in the receptor kinase leading to over-activation of these kinases and their downstream signaling molecules like Ras, Src, and MEK. Many of these kinases become constitutively active and promote uncontrollable cell growth. In some cancers, if the drug targets molecule of the signaling pathways, the resistant cancer cells tend to activate alternative molecules. As an example, the mutations in the EGFR in anaplastic lymphoma kinase (ALK) fusion gene-positive LC after the patient was treated with crizotinib. Acquired resistance to the drug occurred via (ALK)-mutations such as EGFR (L1196M and C1156Y) and some patients had other mechanisms of resistant with both mutations and increase ALK gene copy number [139–141]. The single-nucleotide mutations like L1196 and G1269A were reported in some cases to cause crizotinib resistance in NSCLC [142]. However, sometimes the same effect of the mutation that causes the over-activation can be found via gene over-expression. Overexpression of certain receptors in some LCs with a mutation in the EGFR tyrosine kinase domain causes drug acquired resistance that may occur after the long-term use of drugs inhibitors targeting this kinase [142].

The resistance to EGFR therapy could also involve alteration of the PTEN-PI3K-AKT pathway. The PTEN refers to Phosphatase and tensin homolog which is a tumor suppressor gene that impedes tumor growth via the inhibition of the Akt oncogene that promotes the cell survival through inactivating of some apoptosis mediators [143]. The loss of PTEN results in cancer cells resistance for EGFR inhibitors such as erlotinib that initiates negative regulation in the PI3K-AKT pathway leading to PI3K activation and tumor progression [144,145].
Angiogenesis inhibitors such as bevacizumab can face resistance from cancer cells that involves alteration of VEGF tyrosine kinase receptors (VEGFR) and binding with Neuropilin-1 (NP1) and/or Neuropilin-2 (NP2) [146,147]. When bevacizumab blocks VEGF-A, NP1, and NP2, resistant cancer cells use alternate VEGFR-1 and VEGFR-2 pathways leading to angiogenesis and tumor progression. In NSCLC, the elevated level of expression for both NP1 and NP2 in tissues was found to be correlated with tumor growth [148].

Co-delivery is a targeting strategy applied mainly in the molecular-targeting therapy for the treatment of NSCLC. The first approved epidermal growth factor receptor (EGFR) drug is gefitinib a tyrosine kinase inhibitor (TKI) that is used for treatment of EGFR mutation in NSCLC. The long-term treatments for patients with gefitinib can result in the development of DR. Approximately 90% of EGFR mutations found deletions in exon 19 and single missense and secondary mutation in exon 20 in 50% of patients with the secondary T790M mutations (EGFR T790M) associated with the resistance to gefitinib [137,149–156]. The resistance to gefitinib occurs due to mutated methionine (M) residue which blocks the interaction between the anticancer drug and the active EGFR pocket. In this case, a co-delivery system can be used to overcome resistance issues. Peng et al used mannose-modified liposomal and HER-2 antibodies as a co-delivery system (tLGV) to treat NSCLC with EGFR T790M-mutation [157]. Another liposomal co-delivery system involved the use of PD-L1 nanobody as a ligand in gefitinib-loaded liposomes for treatment of NSCLC with EGFR T790M-positive mutation [158].

2.7. Enhancing DNA repair

DNA repair involves a tangled network of repair mechanism dictated by the specific kind of stimuli and damage to which cells are exposed (Figure 3). These mechanisms include mismatch repair (MMR), nucleotide excision repair (NER), base excision repair (BER), direct reversal (MGMT, ABH2, ABH3), homologous recombination (HR) and non-homologous end joining (NHEJ) pathways. For instance, ionizing radiation induce double-strand breaks (DSBs) mainly repaired by nonhomologous end joining (NHEJ) pathway. On the other hand, mono- and bifunctional alkylators can induce DNA base modifications interfering with DNA synthesis which can be reversed in a mismatch repair-dependent manner [159–161].

Inhibition of DNA repair systems may be a potential strategy to sensitize cancer cells to chemotherapeutic drugs and increase their efficacy. However, even if disrupting DNA repair systems may block the resistance to chemotherapeutic agents, it can also be responsible for the development of new mutations due to genomic instability [162].

CIS-resistant cancer cells showed higher level of DNA damage repair. In addition, it was noted that inhibition of NER pathway can significantly enhance tumor cells sensitivity to CIS. The enhanced DNA repair capability in lung-CSCs was associated to an extensive activation of DNA repair genes in response to CIS-treatment, suggesting it may be the main mechanism involved in resistance insurgence [163,164]. Studies have also highlighted an inverse correlation of ERCC1 (NER pathways) with response to platinum therapy in LC [165]. Apurinic/apyrimidinic endonuclease 1 (APE1) is considered a crucial BER pathway protein due to its activity as intermediate in the processing of potentially cytotoxic DNA damage sites. Moreover, APE1 seems to have a dual role depending on its cellular localization where it carries out DNA repair in the nucleus, while in the cytoplasm its primary role is assumed to be the regulation of mitochondrial DNA repair, possibly together with the regulation of various transcription factors. In LC cells, APE1 is often overexpressed, especially in CIS-resistant cancers [166,167].

Ongoing studies have proved the actual potential of targeting DNA repair elements to prevent or overcome DR. Coadministration of natural compounds such as curcumin (CUR) enhanced of CIS apoptotic activity on CIS-resistant lung adenocarcinoma cells through the inhibition of FANCD2 mono-ubiquitination and inactivation of the Fanconi anemia (FA)/BRCA pathway which is a DNA cross-link damage repair pathway responsible for cellular resistance regulation towards DNA cross-link agents [168]. Similar effect
was also reported by Hong et al. in their work using CIS prodrug (CDDP) and CUR co-encapsulated NPs in treatment of NSCLC. The results of the study showed that the co-delivery of both chemotherapeutic agents using PLGA-based NPs induced synergistic response, increased the therapeutic efficacy and overcame DR [169].

In a different study, polypeptide-based nanocarriers were used for combined targeting of DNA repair and DNA damage-induced cell cycle checkpoint pathways through the inhibition of both mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MAPKAPK-2 or MK2) and Xeroderma Pigmentosa Group A (XPA) [170]. This treatment strategy could be further enhanced by adding CIS to reduce CIS-resistance and improve therapeutic outcomes.

Another successful approach was based on loading demethoxycurcumin (DMC) to self-assembled amphiphilic carbomethyl-hexanoyl chitosan (CHC) nanomatrix. The drug-loaded nanomatrix significantly reduced CIS-induced DR through the suppression of excision repair cross-complementary 1 (ERCC1) in NSCLC. Moreover, the bioavailability and targeting capacity toward cancer cells were improved by preparation of a DMC-polyvinylpyrrolidone core phase followed by the encapsulation in a CHC shell to form a DMC-loaded core-shell hydrogel NPs (DMC-CHC NPs) [171].

2.8. Gene amplification

DR due to gene amplification is estimated to occur in 10% of the cancers. It involves the increase in the number of copies of certain oncogenes inside the resistant cancer cells to several hundred times compared to the drug-sensitive cancer cells which eventually lead to the production of related oncoproteins in large amounts per cell (Figure 3). For instance, the MET gene amplification is found to affect 5–20% of EGFR-TKI treated NSCLC patients who develop resistance to TKI drugs. HER2 amplification also has been recognized as a rare resistant mechanism in lung adenocarcinoma occurring in 1–2% of total cases in patients and tends to be up to 13% in NSCLC patients with resistance to EGFR-TKIs [172–175]. The MET is a proto-oncogene that encodes the MET protein (c-MET) that can result in an increase in tyrosine kinase signaling and excessive cellular division [176]. There is a link between the MET and the third-generation EGFR-TKIs resistance in EGFR mutant (EGFRm) NSCLC cell line (HCC827/ER). Acquired resistance to erlotinib due to amplified MET gene in the cells and associated with hyperactivated MET protein also have resistance to both osimertinib and rociletinib [177]. The use of small molecule MET inhibitor or genetic knockdown to the expression of MET successfully increased the sensitivity of HCC827/ER cells to osimertinib and effectively inhibited the cell growth in vitro and in vivo [177,178].

The amplification of genes was also detected on the MDR1/ABCB1 chromosomal region that encodes the P-gp (P-gp/ABCB1) with overexpression of the ATP-binding cassette pumps in resistant LC cells after being treated with PTX. This resulted in a decrease in cellular accumulation of PTX, an increase in its efflux out of the cancer cells and development of resistance to the drug [44,179–181]. The encapsulation of chemotherapeutic agents into NPs or binding them to polymeric carriers as nanoconjugates can allow them to evade the ABC drug efflux pumps as they come unrecognizable as substrates to be exported. In one study anti-MRP-1 and anti-Bcl2 siRNA were encapsulated in combination with DOX in liposomes. The DDS targeted both pump and non-pump mediated cellular LC resistance leading to suppression of efflux pumps and increase in drug accumulation inside resistant LC cells [182].

2.9. Epigenetic alteration caused drug resistance

Although all cells of the human body have the same exact genes, epigenetic alterations regulate the way genome can be read. These are changes in the chemical structure of DNA that does not change the nucleotide coding sequence but have a profound effect on gene expression. Epigenetic alterations may occur due to adding and exposure to environmental factors, such as diet, exercise, drugs, and chemicals [183–185]. Methylation
and acetylation of DNA are two well-studied epigenetic events that significantly alter the expression of genes, resulting in upregulation of oncogenes and/or downregulation of tumor suppressor genes and development of cancer DR [186].

In eukaryotes, histones mainly serve as a structure guide for several enzymes to provide the necessary platform for RNA polymerase access to its target. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are essential enzymes that regulate histone acetylation, which is the pivotal focus of several studies on post-translational modification mechanism. Most of the common feature displayed by cancerous cells such as evasion of apoptosis, increased angiogenesis and metastasis progression can be linked to epigenetic modulation and to HDAC. A number of studies highlighted the multiple roles of HDAC suggesting it as a potential target for chemotherapy and establishing the basis for developing and use of HDAC inhibitors (HDACi) as co-adjuvant for many anticancer agents for treatment of NSCLC [187,188] PTX co-administration with HDACi SNOH-3 showed reversed DR in PTX-resistant NSCLC cells characterized by overexpression of HDAC1 [189]. Sharma et al. demonstrated the ability of a subset of stem-like cells in NSCLC cell lines to undergo chromatin remodeling following treatment with erlotinib and CIS which allow development of drug insensitivity [190]. However, despite the myriad of pre-clinical work supporting HDACi efficacy as adjuvant of chemotherapy in treatment of NSCLC, they have demonstrated modest efficacy as single agents in clinical trials.

The use of nanocarriers for the delivery of epigenetic agents have noticeably enhanced their ability as co-adjuvants to re-sensitize cancer cells after onset of anticancer DR. Studies on using HDACi-loaded NPs in combination with chemotherapy and radiotherapy demonstrated the enhancement of anti-proliferative effects [191]. For example, to improve the bioavailability of the histone deacetylase inhibitor vorinostat (VOR) and its efficacy in treatment of multidrug resistant cancers, solid lipid NPs (SLNs) were used as carriers. VOR-SLNs were prepared and tested on resistant LC cell line showing improved efficacy, elevated payload capacity and a sustained release profile. The results also showed that lower doses of VOR-SLNs were required to obtain the same cytotoxic effect as free-VOR [192].

Other studies suggested that gefitinib resistance in patients with NSCLC may be correlated to EGFRT790M secondary mutation in those patients after treatment with gefitinib. Peng et al. reported the preparation of a dual-targeted liposome system for the delivery of vorinostat and gefitinib that is decorated with anti-HER-2 antibody and mannose for targeting HER-2-overexpressing tumor cells and mannose receptor-expressed tumor-associated macrophages (TAMs), respectively. The drug-loaded immunoliposomes were able to reverse EGFRT790M-positive NSCLC resistance to gefitinib through the regulation of ROS/NOX3/MsrA axis and reconfiguration of TAMs [157,193].

Table 1: Preclinical studies Nano-based strategy to overcome DR in LC

| Type of Nanomedicine | Drug load | Targets                         | Cells/cancer               | References |
|----------------------|-----------|---------------------------------|----------------------------|------------|
| PCL-SS-PMAA micelles | CIS/PTX   | pH/redox responsive             | In vitro NCI-H358 LC cells | [35]       |
| Magnetic NPs         | Manganese Dioxide | Redox responsive/ radiosensitive | In vitro Hypoxic induced Gefitinib-resistant PC9 human LC cells (PC9GR) | [194] |
| cRGDyK-SPCS micelles | PTX       | pH responsive/ protein targeting | In vitro Luc-A549 LC cells | [37]       |
**Mesoporous silica nanoparticle decorated with PD-L1 antibody (ARAC)**

| PLGA NPs | DOX/Cyclosporin | P-gp | Immune modulation | In vivo LLC-JSP murine LC cells (200K) inoculated in right flank of C57BL/6 female mice |
|----------|-----------------|------|-------------------|-----------------------------------------------------------------|

**TPGS1000-TPP**

| Paclitaxel | TPGS1000-TPP | P-gp and mitochondrial targeting | In vitro PTX-resistant LC A549 cell line (A549-Taxol) and In vivo A549-Taxol cells implanted subcutaneously into female BALB/c mice |
|------------|--------------|---------------------------------|-----------------------------------------------------------------|

**Graphene**

| TRAIL + DOX | FADD | Graphene | TRAIL + DOX | FADD | Human LC | TRAIL + DOX | FADD | Human LC |
|-------------|------|----------|-------------|------|-----------|-------------|------|----------|

**Gold**

| Gefitinib | EGFR | Gold | Gefitinib | EGFR | Human adenocarcinoma and NSCLC (in vitro) | Gefitinib | EGFR | Human adenocarcinoma and NSCLC (in vitro) |
|-----------|------|------|-----------|------|-----------------------------------------|-----------|------|-----------------------------------------|

**Liposomal**

| Erlotinib | EGFR | Liposomal | Erlotinib | EGFR | Human breast and LC | Erlotinib | EGFR | Human breast and LC |
|-----------|------|-----------|-----------|------|-------------------|-----------|------|-------------------|

**Liposomal**

| siRNA (MRP1/BCL2) DOX | MRP1/BCL2 | Liposomal | siRNA (MRP1/BCL2) DOX | MRP1/BCL2 | Human LC | siRNA (MRP1/BCL2) DOX | MRP1/BCL2 | Human LC |
|------------------------|-----------|-----------|------------------------|-----------|-----------|------------------------|-----------|-----------|

**Liposomal**

| Lonidamine + epirubicin (in a separate liposomal formulation) | Mitochondrial hexokinase | Liposomal | Lonidamine + epirubicin (in a separate liposomal formulation) | Mitochondrial hexokinase | Human LC | Lonidamine + epirubicin (in a separate liposomal formulation) | Mitochondrial hexokinase | Human LC |
|---------------------------------------------------------------|--------------------------|-----------|---------------------------------------------------------------|--------------------------|-----------|---------------------------------------------------------------|--------------------------|-----------|

**Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 11 January 2022**

**doi:10.20944/preprints202201.0146.v1**
| Liposomal TRAIL + DOX (in separate NPs) | FADD | Human LC [200] |
| Nanoliposomes in combination with radiation therapy | CIS alkylating and crosslinking DNA: Sensation to radiation lesions | Human Lewis lung carcinoma A549 cells subcutaneously inoculated into C57BL/6N mice, In vivo model [201] |
| Nanoliposomes in combination with radiation therapy | siRNA (c-Myc) Gemcitabine monophosphate | c-Myc Human LC [202] |
| Nanoliposomes in combination with radiation therapy | SiRNA (VEGF) Gemcitabine monophosphate | VEGF Human LC [203] |
| (MPEG-PCL) micelles CUR + DOX | ABC pumps/NF-κB | Murine LC [204] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-delivery of drug and gene-enhanced antitumor effect | LC [205] |
| Polymeric micelles Paclitaxel and survivin shRNA which down-regulate survivin gene expression by RNA interference | Co-deliver
2.10. Clinical studies using nanotechnology for management of DR in LC

The potential use of NPs in treatment of drug resistant LC was explored in many clinical trials (Table 2). In 2012, the FDA approved the first nano-formulation for treatment of NSCLC patients Abraxane® which consists of a solvent-free albumin-bound PTX-NPs based on its significant improved clinical trial outcomes [209]. Other nano-formulations has been the subject of various clinical trials and showed promising therapeutic outcomes in treatment of resistant LC (http://www.clinicaltrials.gov). Examples of clinical studies that aimed to evaluate the efficacy and safety of NPs loaded with various therapeutic agents to target LC at different stages are discussed in table 2.

| Type of NPs | Cargo/Therapy | Status       | Patient/condition | Stage  | ClinicalTrials.gov Identifier: |
|-------------|---------------|--------------|-------------------|--------|--------------------------------|
| Liposomes   | Drug: LY01610 (Irinotecan hydrochloride liposome injection) | Recruiting   | SCLC              | Phase 2 | NCT04381910                   |
| Liposomes   | Device: Liposomal DOX Combined With ifosfamide | Unknown      | SCLC              | Phase 2 | NCT01872416                   |
| Liposomes   | Drug: PLM60 | Recruiting   | SCLC              | Phase 2 | NCT04352413                   |
| Liposomes   | Drug: MRX34 | Terminated   | SCLC              | Phase 1 | NCT01829971                   |
| Polymeric-PEG | Drug: ADI-PEG 20 (Arginine deiminase pegylated) | Terminated   | SCLC              | Phase 2 | NCT01266018                   |
| Polymeric-PEG | Drug: LCL161 | Terminated   | LC                | Phase 1 | NCT02649673                   |
| Polymeric-PEG | Drug: Topotecan Drug: Pegylated GCSF (PEG-GCSF) | Terminated   | SCLC              | Phase 2 | NCT01876446                   |
| Polymeric-PEG | Drug: Irinotecan Pegylated | Completed    | SCLC              | Phase 2 | NCT01876446                   |
| Polymeric-PEG | Drug: Irinotecan Pegylated | Recurrent Small Cell | LC               | Phase 2 | NCT01876446                   |
| Polymeric-PEG | Drug: PEG-rhG-CSF | Unknown      | SCLC              | Not Applicable | NCT03776604                  |
| Polymeric-PEG | Drug: ADI-PEG 20 | Completed | – Solid tumors – NSCLC | Phase 1 | NCT01497925                   |
| Polymeric-PEG | Drug: Recombinant Human Endostatin (PEG-ENDO) | Recruiting | – Solid tumors – NSCLC | Phase 1 | NCT04413227                   |
| Polymeric-PEG Drug: PEG-rhG-CSF | Completed | − Malignant Solid Tumor − LC | Phase 4 | NCT02805166 |
|---------------------------------|-----------|-----------------------------|--------|-------------|
| − Drug: YPEG-rhG-CSF, 20μg/kg, single s.c. at 48 h after chemotherapy for each experimental cycle  |  |  |  |  |
| − Drug: YPEG-rhG-CSF, 30μg/kg, single s.c. at 48 h after chemotherapy for each experimental cycle  |  |  |  |  |
| − Drug: YPEG-rhG-CSF, 45μg/kg, single s.c. at 48 h after chemotherapy for each experimental cycle  |  |  |  |  |
| − Drug: PEG-rhG-CSF, 100μg/kg, single s.c. at 48 h after chemotherapy for each experimental cycle  |  |  |  |  |

| Polymeric-PEG Drug: ADI-PEG 20 | Terminated | Non-squamous NSCLC | Phase 1 | NCT02029690 |
|---------------------------------|------------|--------------------|--------|-------------|
| − Drug: EP0057  |  |  |  |  |
| − Drug: laparib  |  |  |  |  |

| NPs Drug: BIND-014 | Completed | NSCLC | Phase 2 | NCT01792479 |
|--------------------|-----------|------|--------|-------------|
| Drug: BIND-014 (Docetaxel NPs for Injectable Suspension) | Completed | − KRAS Positive Patients With NSCLC − Squamous Cell NSCLC | Phase 2 | NCT02283320 |

| NPs Drug: AGuIX Radiation: Radiotherapy | Recruiting | NSCLC | Phase 2 | NCT04789486 |
|----------------------------------------|------------|------|--------|-------------|
|  |  |  |  |  |

| Micelles Drug: PTX (Genexol®) | Completed | NSCLC | Phase 2 | NCT01023347 |
|-----------------------------|-----------|------|--------|-------------|
### Micelles
- Drug: PTX-loaded polymeric micelle (Genexol-PM®)
- Drug: PTX Micelles for Injection
- Drug: PTX Injection
- Drug: CIS

### Albumin
- Drug: nanoparticle albumin-bound PTX/carboplatin
- Drug: carboplatin
- Drug: erlotinib hydrochloride
- Drug: PTX albumin-stabilized nanoparticle formulation
- Radiation: radiation therapy

### Albumin
- Drug: HLX10
- Drug: carboplatin and nab paclitaxel
- Drug: Placebo

### Albumin
- Drug: nanoparticle albumin-bound PTX

### Albumin
- Drug: Albumin Paclitaxel
- Drug: Simvastatin

### Albumin
- Drug: PTX/Albumin-Bound PTX
- Drug: IBI308

### Radioactive
- Drug: 18F-Fluoropaclitaxel (FPAC)

| Drug                                      | Status       | Disease  | Phase | NCT Number   |
|-------------------------------------------|--------------|----------|-------|--------------|
| PTX-loaded polymeric micelle              |              |          |       | NCT02667743 |
| PTX Micelles for Injection                | Active, not recruiting | NSCLC    | Phase 3| NCT01872403 |
| PTX Injection                             |              |          |       |              |
| CIS                                        |              |          |       |              |
| nanoparticle albumin-bound PTX/carboplatin| Unknown      | NSCLC    | Phase 2|              |
| carboplatin                               |              |          |       |              |
| erlotinib hydrochloride                   |              |          |       |              |
| PTX albumin-stabilized nanoparticle for    | Completed    | LC       | Phase 2| NCT00553462 |
| tumor therapy                             |              |          |       |              |
| HLX10                                      | Recruiting   | NSCLC    | Phase 3| NCT04033354 |
| carboplatin and nab paclitaxel             |              |          |       |              |
| Placebo                                    |              |          |       |              |
| nanoparticle albumin-bound PTX             | Unknown      | NSCLC    | Phase 2| NCT02016209 |
| Albumin paclitaxel                         | Recruiting   | SCLC     | Phase 2| NCT04698941 |
| Simvastatin                                |              |          |       |              |
| PTX/Albumin-Bound PTX                      | Recruiting   | SCLC     | Phase 2| NCT04056949 |
| IBI308                                     |              |          |       |              |
| 18F-Fluoropaclitaxel                       | Terminated   | LC       | Phase 1| NCT01086696 |
| TargomiRs                                  | Completed    | NSCLC    | Phase 1| NCT02369198 |

*Source: https://clinicaltrials.gov/

### 3. Current limitations and future perspectives of nanomedicine aimed at overcoming drug resistance

Cancer therapy is the primary and most attractive field for nanomedicine applications, also thanks to the history of success of Doxil® and Abraxane® as main representatives mentioned in several clinical studies [46,47]. Nanoscale DDS hold promise for new insights and innovative solutions to overcome conventional chemotherapy issues,
allowing precise delivery of anticancer agents to specific malignant sites and ensure efficient cellular internalization. This can lead to the complete tumor eradication and potentially useful to overcome chemo-resistance in cancers [48].

Even though many NPs have achieved important milestones as potential therapies [49-51], still most of them fail to meet the clinical standards. In addition, clinically approved NPs have proved to be effective in reducing drugs toxicity; yet their application not always resulted in a better clinical outcome. Deficiency in understanding the biological mechanisms, complex design and absence of accurate characterization techniques in addition to the high cost of manufacturing have jeopardized nanomedicines clinical translation.

4. Biological Aspects

Biodistribution modulation, biological barrier breaching, and complex heterogeneity of human diseases are the main biological factors that must be taken in consideration to design and produce NPs able to reach clinical trials. Random distribution and accumulation at nontarget sites remain the central obstacles for development of effective nanomedicines. Therefore, an alternative development strategy that relies on a disease-driven approach, rather than the conventional formulation-driven approach, is currently needed. This means that the DDS engineering should be the core of research. To do so, a solid understanding of the connections between biology and technology must be conquered [210]. Studying the biological processes that control barriers functions and their involvement in disease progression, together with discovering new materials, will ensure the development of NPs capable of overcoming the obstacles for efficacious and site-specific delivery [17].

5. Formulation Drawbacks

In order to deal with the complexity of malignant tumors, it is crucial to have a consistent and highly reproducible formulation prior to the clinical phases [211]. Novel antineoplastic delivery systems are more and more based on the development of multifunctional NPs with specific targeting and image contrast enhancing properties added to the basic structure of the carriers. The addition of specific tags to the nanocarriers adds further complexities to the synthesis process, increases the costs, introduces complex interactions, and effects in vivo and hinders regulatory affairs. Targeted therapeutics are surely attractive and most of the times seem to be the right solution to the conventional chemotherapeutic issues. Nevertheless, their synthesis and purification, together with choosing the most fitting and effective ligand-receptor couple can make their realization challenging and risky, not always resulting in a positive outcome or a feasible production. Moreover, it is known that even the smallest modification in the structure can affect the binding features leading to steric hindrances, conformational changes and less efficacy. The complexity further increases when it involves nanomedicines carrying more than just one active compound as this can significantly affect their pharmacological profile. In order to overcome these limitations, novel bioconjugation methods are in developing phases, among them the click chemistry concept has been regaining a great deal of interest, basing new NPs design on easier drug production in order to guarantee straightforward and economic synthesis of large libraries of new compounds and reduce the costs [212–214]. Moreover, to obtain clinical approval, it is fundamental for the entire process to rely on a stable and reproducible product. Unfortunately, in most of the cases, NPs tested in preclinical studies are tendentially synthesized in small batches and their scale-up for higher production is not always possible, even for clinical studies [215,216]. There is also the need for specific regulatory guidelines and streamlined approval process which address the complexity of nanomedicine characterization together with pharmacological and toxicological issues [217]. All these elements represent the biggest challenges that prevents nanomedicines to reach clinical phases.
5. New approaches for use of nanomedicine in treatment of resistant LC

Novel receptor-specific targeting strategies exploiting the peculiar characteristics of tumor microenvironment could be useful to overcome several complications and hurdles associated with targeted NPs and significantly reduce cancer resistance to chemotherapy. While conventional approaches rely on environmental stimuli to guide NPs delivery and localization, some new formulation aims to manipulate their path externally. For instance, it was observed that iron-based NPs loaded with anticancer drugs can be directly guided by a magnetic field gradient in the precise tumor location [218]. Alexiou et al. have been using magnetic NPs, in particular the commercially available ferrofluids, as drug carriers injected intravenously. The application of an external magnetic field at the tumor site post injection resulted in accumulation of the NPs at the tumor area and reduced the systemic toxicity of the drug. Furthermore, magnetic NPs may function as carriers for multiple anticancer agents, e.g. genes, cancer-specific antibodies and radio nuclides [218].

Alternatively, photodynamic therapy (PDT) has emerged in the last decade as a potential therapeutic approach for cancer management. Since most photosensitizers have predominantly hydrophobic characteristics, appropriate delivery systems are required [219–223]. In vitro studies on LC cell lines using nanocarriers loaded with photosensitizers showed interesting results that involved the induction of mitochondrial dysfunction through decoration of targeting moieties on the nanocarriers. Work of Shi et al. focused on liposomal-based nanomedicine (L@BP) loaded with mitochondria-anchored photosensitizer (Cy-Br) and PTX had interesting outcomes where it showed the successful release and accumulation of both agents in the tumor site and an enhanced therapeutic efficacy on PTX-resistant LC cells, putting the basis for its potential use on MDR cancers [224].

Another emerging strategy to prevent DR involves using NPs for the delivery of siRNAs. Delivering different siRNAs could concurrently silence several genes, including those genes responsible for DR. siRNAs physicochemical features impede their cellular uptake, since they are not able of easily crossing phospholipid membranes. Therefore, appropriate carriers and development of new RNAi technology are required. Genome editing technology may provide a platform for the development of newer and better approaches.

One of the possible strategies that can be useful in developing more effective NPs DDS for management of resistance to anticancer drugs is the integration of biocompatible compounds. For example, Reshma et al. have proposed the use of biopolymers such as tamarind seed polysaccharide PST to prepare PTX-loaded NPs through epichlorohydrin crosslinking. PST-PTX NPs were able to downregulate multidrug resistance related proteins, as P-gp and BCRP, in resistant cells suggesting the potential of these particles as MDR inhibitors [225].

6. Conclusion

There are many mechanisms involved in the development of DR to chemotherapy in treatment of LC. Nanotechnology has shown promising results in delivery of chemotherapeutic agents by increasing their circulation time, offering precise multiple targeting, enhancing drug accumulation at the tumor site, improving cellular uptake into the cytoplasm and/or nuclei of cancer cells, and effectively carrying combinations of therapeutic payloads. Nanotechnology has also shown great potential in overcoming DR in LC by inhibiting some mechanisms like the overexpression of drug efflux transporters, tumor microenvironment, activation of DNA repair pathway, prevention of cell apoptosis, and cancer stem cell. Currently, various nanomedicines have been widely used, and some others are already in clinical trials. It is therefore expected that current progress of NPs development may provide new strategies for the treatment of cancer resistance. Although some successes have been achieved in the nanomedicine preclinical applications, many challenges must be overcome to speed up the clinical transformation of nanomedicine.
Author Contributions: Conceptualization, M.H. and K.G.; resources, M.H. and K.G.; writing original draft preparation, M.H., A.E., V.P., A.N.F., M.A.A. and K.G.; writing review and editing, M.H., A.E. V.P., ZH, GK and K.G.; supervision, M.H., V.P. and K.G.; project administration, M.H. and K.G.; funding acquisition, M.H. and K.G.; All authors have read and agreed to the published version of the manuscript.”.

Funding: This research was funded by UOS targeted research project, 2101110345 to MH.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Dela Cruz, C.S.; Tanoue, L.T.; Matthay, R.A. Lung Cancer: Epidemiology, Etiology, and Prevention. Clin. Chest Med. 2011, 32, 605–644, doi:10.1016/J.CCM.2011.09.001.
2. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Cancer statistics for the year 2020: An overview. Int. J. Cancer 2021, 149, 778–796, doi:10.1002/IJC.33588.
3. Sutherland, K.D.; Berns, A. Cell of origin of lung cancer. Mol. Oncol. 2010, 4, 397–403, doi:10.1016/j.molonc.2010.05.002.
4. Sutrakdar, K.B.; Amin, M.L. Nanotechnology in Cancer Drug Delivery and Selective Targeting. ISRN Nanotechnol. 2014, 2014, 939378, doi:10.1155/2014/939378.
5. Jabir, N.R.; Tabrez, S.; Ashraf, G.M.; Shakil, S.; Damanbouri, G.A.; Kamal, M.A. Nanotechnology-based approaches in anticancer research. Int. J. Nanomedicine 2012, 7, 4391–4408, doi:10.2147/IJNN.S33838.
6. Mansoori, B.; Mohammadi, A.; Davudian, S.; Shirjarg, S.; Baradaran, B. The different mechanisms of cancer drug resistance: A brief review. Adv. Pharm. Bull. 2017, 7, 339–348, doi:10.15171/apb.2017.041.
7. Sarkar, S.; Horn, G.; Moulton, K.; Oza, A.; Byler, S.; Kokulos, S.; Longacre, M. Cancer development, progression, and therapy: an epigenetic overview. Int. J. Mol. Sci. 2013, 14, 21087–21113, doi:10.3390/ijms141021087.
8. Patra, J.K.; Das, G.; Fraceto, L.F.; Campos, E.V.R.; Rodriguez-Torres, M.D.P.; Acosta-Torres, L.S.; Diaz-Torres, L.A.; Grillo, R.; Swamy, M.K.; Sharma, S.; et al. Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnology 2018, 16, 71, doi:10.1186/S12951-018-0392-8.
9. Palazzolo, S.; Bayda, S.; Hadla, M.; Caligiuri, I.; Corona, G.; Toffoli, G.; Rizzolio, F. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes. Curr. Med. Chem. 2018, 25, 4224–4268, doi:10.2174/0929867324666170830113755.
10. Bahman, F.; Pittalà, V.; Haider, M.; Greish, K. Enhanced Anticancer Activity of Nanof ormulation of Dasatinib against Triple-Negative Breast Cancer. J. Pers. Med. 2021, 11, doi:10.3390/jpm11060559.
11. Awad, N.S.; Haider, M.; Paul, V.; AlSawafah, N.M.; Jagal, J.; Pasricha, R.; Hussein, G.A. Ultrason-Surgured Liposomes Encapsulating Quantum Dots as Safe Fluorescent Markers for Colorectal Cancer. Pharmaceutics 2021, 13, doi:10.3390/pharmaceutics13120273.
12. Haider, M.; Zaki, K.Z.; El Hamshary, M.R.; Hussain, Z.; Orive, G.; Ibrahim, H.O. Polymeric nanocarriers: A promising tool for early diagnosis and efficient treatment of colorectal cancer. J. Adv. Res. 2021, doi:https://doi.org/10.1016/j.jare.2021.11.008.
13. Ahmed, J.S.; El Hosary, R.; Hassan, M.A.; Haider, M.; Abd-Rabo, M.M. Efficacy and Safety Profiles of Oral Atr vosstavatin-Loaded Nanoparticles: Effect of Size Modulation on Biodistribution. Mol. Pharm. 2018, 15, 247–255, doi:10.1021/acs.molpharmaceut.7b00856.
14. Haider, M.; Elsherinby, A.; Jagal, J.; Hubatová-Vacková, A.; Ahmed, J.S. Optimization and evaluation of poly(Lactide-co-glycolide) nanoparticles for enhanced cellular uptake and efficacy of paclitaxel in the treatment of head and neck cancer. Pharmaceutics 2020, doi:10.3390/pharmaceutics12090828.
15. Kim, E.-S.; Ahn, E.H.; Chung, E.; Kim, D.-H. Recent advances in nanobiotechnology and high-throughput molecular techniques for systems biomedicine. Mol. Cells 2013, 36, 477–484, doi:10.1007/s10059-013-0304-6.
16. Haider, M.; Abdin, S.M.; Kamal, L.; Orive, G. Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics 2020, 12.
17. Blanco, E.; Shen, H.; Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 2015, 33, 941–951, doi:10.1038/nbt.3330.
18. Kalyane, D.; Raval, N.; Maheshwari, R.; Tambe, V.; Kalia, K.; Tekade, R.K. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater. Sci. Eng. C 2019, 98.
19. Sadeghi Rad, H.; Monkman, J.; Warkiani, M.E.; Ladwa, R.; O’Byrne, K.; Rezaei, N.; Kulasinghe, A. Understanding the tumor microenvironment for effective immunotherapy. Med. Res. Rev. 2021, 41, 1474–1498, doi:10.1002/med.21765.
20. Poltavets, V.; Kochetkova, M.; Pitson, S.M.; Samuel, M.S. The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity. Front. Oncol. 2018, 8, 431, doi:10.3389/oncology.2018.00431.
21. Baghban, R.; Roshangar, L.; Jahanban-Esfahan, R.; Seidi, K.; Ebrahimi-Kalan, A.; Jaymand, M.; Kolahian, S.; Javaheri, T.; Zare, P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 2020, 18, 59, doi:10.1186/s12964-020-0530-4.
22. Tan, Z.; Xue, H.; Sun, Y.; Zhang, C.; Song, Y.; Qi, Y. The Role of Tumor Inflammatory Microenvironment in Lung Cancer. Front. Pharmacol. 2021, 12, 688625, doi:10.3389/fphar.2021.688625.

23. Fernandes, C.; Suares, D.; Yergeri, M.C. Tumor Microenvironment Targeted Nanotherapy. Front. Pharmacol. 2018, 0, 1230, doi:10.3389/FPHAR.2018.01230.

24. Altorki, N.K.; Markowitz, G.J.; Gao, D.; Port, J.L.; Saxena, A.; Stiles, B.; McGraw, T.; Mittal, V. The lung microenvironment: an important regulator of tumor growth and metastasis. Nat. Rev. Cancer 2018 191 2018, 19, 9–31, doi:10.1038/s41568-018-0081-9.

25. LaFlamme, B. Transcriptional cross-talk between tumor and stromal cells. Nat. Genet. 2014, 46, 933–933, doi:10.1038/ng.3085.

26. Stankovic, B.; Bjørhovde, H.A.K.; Skarshaug, R.; Aamodt, H.; Frafjord, A.; Müller, E.; Hammarström, C.; Beraki, K.; Bakkevold, E.S.; Woldbæk, P.R.; et al. Immune Cell Composition in Human Non-Small Cell Lung Cancer. Front. Immunol. 2018, 9, 3101, doi:10.3389/fimmu.2018.03101.

27. Carrasco-Esteban, E.; Domínguez-Rullán, J.A.; Barrionuevo-Castillo, P.; Pelári-Mici, L.; Leaman, O.; Sastre-Gallego, S.; López-Campos, F. Current role of nanoparticles in the treatment of lung cancer. J. Clin. Transl. Res. 2021, 7, 140, doi:10.18053/jctres.07.202102.005.

28. Mangal, S.; Gao, W.; Li, T.; Zhou, Q.T. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: Challenges and opportunities. Acta Pharmacol. Sin. 2017, 38, 782–797, doi:10.1038/aps.2017.34.

29. Thakor, A.S.; Gambhir, S.S. Nanooncology: The future of cancer diagnosis and therapy. CA. Cancer J. Clin. 2013, 63, 395–418, doi:10.3322/caac.21399.

30. Gu, F.; Hu, C.; Tai, Z.; Yao, C.; Tian, J.; Zhang, L.; Xia, Q.; Gong, C.; Gao, Y.; Gao, S. Tumor microenvironment-responsive lipic acid nanoparticles for targeted delivery of docetaxel to lung cancer. Sci. Rep. 2016, 6, 1–15, doi:10.1038/srep36281.

31. Palanikumar, L.; Al-Hosani, S.; Kalmouni, M.; Nguyen, V.P.; Ali, L.; Pasiecha, R.; Barrera, F.N.; Magzoub, M. pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics. Commun. Biol. 2020 31 2020, 3, 1–17, doi:10.1038/s42003-020-0817-4.

32. Uthaman, S.; Huh, K.M.; Park, I.K. Tumor microenvironment-responsive nanoparticles for cancer therapeutic applications. Biomater. Res. 2018, 22, doi:10.1186/s40824-018-0132-z.

33. Engelberg, S.; Netzer, E.; Assaraf, Y.G.; Livney, Y.D. Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo. Cell Death Dis. 2019, 10, 1–14, doi:10.1038/s41419-019-1870-0.

34. Babu, A.; Templeton, A.K.; Munshi, A.; Ramesh, R. Nanoparticle-based drug delivery for therapy of lung cancer: Progress and challenges. J. Nanomater. 2013, doi:10.1155/2013/863951.

35. Lo, Y.L.; Huang, X.S.; Chen, H.Y.; Huang, Y.C.; Liao, Z.X.; Wang, L.F. ROP and ATRP fabricated redox sensitive micelles based on PCL-SS-PMAA diblock copolymers to co-deliver PTX and CDDP for lung cancer therapy. Colloids Surfaces B Biointerfaces 2021, 198, doi:10.1016/j.colsurfb.2020.111443.

36. Cho, M.H.; Choi, E.-S.; Kim, S.; Goh, S.-H.; Choi, Y. Redox-Responsive Manganese Dioxide Nanoparticles for Enhanced MR Imaging and Radiotherapy of Lung Cancer. Front. Chem. 2017, 0, 109, doi:10.3389/FCHEM.2017.00109.

37. Yuan, Z.Q.; Li, J.Z.; Liu, Y.; Chen, W.L.; Yang, S. Di; Zhang, C.G.; Zhu, W.J.; Zhou, X.F.; Liu, C.; Zhang, X.N. Systemic delivery of micelles loading with paclitaxel using N-succinyl-palmitoyl-chitosan decorated with cRGDyK peptide to inhibit non-small-cell lung cancer. Int. J. Pharm. 2015, 492, 141–151, doi:10.1016/j.ijpharm.2015.07.022.

38. Siriwon, N.; Bejan, D.; Sherif, P.; Pdx, R.; Wang, R.; Pharmaceuticals, P.; Nelson, M.; Zaidan, H.; Hoang, N.; Bindal, A.; et al. Development of novel immunotherapy based on nanoparticle co-delivering PLK1 and PD-L1 inhibitors for lung cancer treatment Moataz Reda PDX Pharmaceuticals Worapor Ngamcherdtrakul PDX Pharmaceuticals. PREPRINT 2021, doi:10.21203/rs.3.rs-142908/V1.

39. Fletcher, J.I.; Williams, R.T.; Henderson, M.J.; Norris, M.D.; Haber, M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist. Updat. 2016, 26, 1–9, doi:10.1016/j.drup.2016.03.001.

40. Bar-Zeev, M.; Livney, Y.D.; Assaraf, Y.G. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance. Drug Resist. Updat. 2017, 31, 15–30, doi:10.1016/j.drup.2017.05.002.

41. Gillet, J.-P.; Gottesman, M.M.; JP, G.; MM, G.; Gillet, J.-P.; Gottesman, M.M. Mechanisms of Multidrug Resistance in Cancer; Methods Mol Biol 2010; Vol. 596, pp. 47–76.

42. Dong, Y.; Fong, S.S. Poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26, 6068–6076, doi:10.1016/j.biomaterials.2005.03.021.

43. Peng, S.; Wang, J.; Lu, C.; Xu, Z.; Chai, J.J.; Ke, Q.; Deng, X.Z. Emodin enhances cisplatin sensitivity in non-small-cell lung cancer through Pgp downregulation. Oncol. Lett. 2021, 21, 1–1, doi:10.3892/OL.2021.12491.

44. Jang, S.H.; Guillaume Wientjes, M.; Au, J.L.S. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J. Pharmacol. Exp. Ther. 2001, 298, 1236–1242.

45. Galletti, E.; Magnani, M.; Renzulli, M.L.; Botta, M. Paclitaxel and docetaxel resistance: Molecular mechanisms and development of new generation taxanes. ChemMedChem 2007, 2, 920–942, doi:10.1002/cmdc.200600308.

46. Bergman, A.M.; Pinedo, H.M.; Taliantidis, I.; Veerman, G.; Loves, W.J.P.; Van Der Wilt, C.L.; Peters, G.J. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br. J. Cancer 2003, 88, 1963–1970, doi:10.1038/sj.bjc.6601011.

47. Berger, W.; Setinek, U.; Hollaus, P.; Zidek, T.; Steiner, E.; Elbing, L.; Cantonati, H.; Attens, J.; Geur, A.; Micksche, M. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: Prognostic implications. J. Cancer Res. Clin. Oncol. 2005, 131, 355–363, doi:10.1007/s00432-004-0653-9.
48. Chen, Z.J.; Le, H.B.; Zhang, Y.K.; Qian, L.Y.; Raja Sekhar, K.; Li, W.D. Lung Resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance. J. Int. Med. Res. 2011, 39, 1693–1700, doi:10.1177/0300060511422302.

49. Chen, S.; Bie, M.; Wang, X.; Fan, M.; Chen, B.; Shi, Q.; Jiang, Y. PGRN exacerbates the progression of non-small cell lung cancer via PI3K/AKT/Bcl-2 antiapoptotic signaling. Genes Dis. 2021, doi:10.1016/j.gendis.2021.05.005.

50. Ke, W.; Zhao, X.; Lu, Z. Foeniculum vulgare seed extract induces apoptosis in lung cancer cells partly through the down-regulation of Bcl-2. Biomed. Pharmacother. 2021, 135, doi:10.1016/j.biopha.2020.111213.

51. Zhang, S.; Liu, N.; Ma, M.; Huang, H.; Handley, M.; Bai, X.; Shan, F. Methionine enkephalin (MENK) suppresses lung cancer by regulating the Bcl-2/Bax/caspase-3 signaling pathway and enhancing natural killer cell-driven tumor immunity. Int. Immunopharmacol. 2021, 98, doi:10.1016/j.intimp.2021.107837.

52. Tan, X.; Shi, L.; Banerjee, P.; Liu, X.; Guo, H.F.; Yu, J.; Bota-Rabassadas, N.; Rodríguez, B.L.; Gibbons, D.L.; Russell, W.K.; et al. A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma. J. Clin. Invest. 2021, 131, doi:10.1172/JCI137186.

53. Zhang, Y.; Han, C.Y.; Duan, F.G.; Fan, X.-X.; Yao, X.-J.; Parks, R.J.; Tang, Y.-J.; Wang, M.-F.; Liu, L.; Tsang, B.K.; et al. p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling. Cancer Cell Int. 2019 19 2019, 19, 1–13, doi:10.1186/S12935-019-0910-2.

54. Gibbons, D.L.; Byers, L.A.; Kurie, J.M. Smoking. p53 mutation, and lung cancer. Mol. Cancer Res. 2014, 12, 3–13, doi:10.1158/1541-7766.MCR-13-0593.

55. Murakami, M.; Cabral, H.; Matsumoto, Y.; Wu, S.; Kano, M.R.; Yamori, T.; Nishiyama, N.; Kataoka, K. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci. Transl. Med. 2011, 3, 64ra2, doi:10.1126/scitranslmed.3001385.

56. Ahmad, J.; Akhter, S.; Ahmed Khan, M.; Wahajuddin, M.; H. Greig, N.; Amjad Kamal, M.; Midoux, P.; Fichon, C. Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. Curr. Pharm. Des. 2016, 22, 4360–4373, doi:10.2174/1381612822666160617111211.

57. Xu, L.; Li, H.; Wang, Y.; Dong, F.; Wang, H.; Zhang, S. Enhanced activity of doxorubicin in drug resistant A549 tumor cells by encapsulation of P-glycoprotein inhibitor in PLGA-based nanovectors. Oncol. Lett. 2014, 7, 387–392, doi:10.3892/ol.2013.1711.

58. Pramual, S.; Lirdprapamongkol, K.; Jouan-Hureaux, V.; Barberi-Heyob, M.; Frochot, C.; Svasti, J.; Niamsiri, N. Overcoming the diverse mechanisms of multidrug resistance in lung cancer cells by photodynamic therapy using pTHPP-loaded PLGA-lipid hybrid nanoparticles. Eur. J. Pharm. Biopharm. 2020, 149, 218–228, doi:10.1016/j.ejpb.2020.02.012.

59. Zhou, J.; Zhao, W.Y.; Ma, X.; Ju, R.J.; Li, X.Y.; Li, N.; Sun, M.G.; Shi, J.F.; Zhang, C.X.; Lu, W.L. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in-resistant lung conjugate. Biomed. Polym. 2018, 34, 3626–3638, doi:10.1016/j.biomaterials.2013.01.078.

60. Tang, D.; Zhao, X.; Zhang, L.; Wang, Z.; Wang, C. Identification of hub genes to regulate breast cancer metastasis to brain by bioinformatics analyses. J. Cell. Biochem. 2019, 120, 9522–9536, doi:10.1002/jcb.29228.

61. Ma, S.; Li, X.; Ran, M.; Ji, M.; Gou, J.; Yin, T.; He, H.; Wang, Y.; Zhang, Y.; Tang, X. Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer. Int. J. Pharm. 2021, 601, 120577, doi:10.1016/j.ijpharm.2021.120577.

62. Wen, Z.M.; Jie, J.; Zhang, Y.; Liu, H.; Peng, L.P. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer. Biochem. Biophys. Res. Commun. 2017, 493, 1430–1437, doi:10.1016/j.bbrc.2017.09.132.

63. Li, B.; Li, Q.; Mo, J.; Dai, H. Drug-loaded polymeric nanoparticles for cancer stem cell targeting. Front. Pharmacol. 2017, 8, 51, doi:10.3389/fphar.2017.00051.

64. Prabavathy, D.; Swarnalatha, Y.; Ramadoss, N. Lung cancer stem cells—origin, characteristics and therapy. Stem Cell Invest. 2018, 5, doi:10.21037/SCI.2018.02.01.

65. MAIUTHED, A.; CHANTARWONG, W.; CHANVORACHOTE, P. Lung Cancer Stem Cells and Cancer Stem Cell-targeting Natural Compounds. Anticancer Res. 2018, 38, 3797–3809, doi:10.21873/ANTICANRES.12663.

66. Masciale, V.; Grisendi, G.; Banchelli, F.; D’Amico, M.; Maiorana, A.; Sighinolfi, P.; Stefani, A.; Morandi, U.; Dominici, M.; Aramini, B. Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study. Front. Oncol. 2019, 9, 1394, doi:10.3389/fonc.2019.01394.

67. Herreros-Pomares, A.; de-Mayo-Girones, J.D.; Calabug-Fariñas, S.; Lucas, R.; Martínez, A.; Pardo-Sánchez, J.M.; Alonso, S.; Blasco, A.; Guijarro, R.; Martorell, M.; et al. Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer. Cell Death Dis. 2019, 10, 1–14, doi:10.1038/s41419-019-1898-1.

68. Li, Y.; Shi, S.; Ming, Y.; Wang, L.; Li, C.; Luo, M.; Li, Z.; Li, B.; Chen, J. Specific cancer stem cell-therapy by albumin nanoparticles functionalized with CD44-mediated targeting. J. Nanobiotechnology 2018, 16, 1–15, doi:10.1186/s12951-018-0424-4.

69. Liu, D.; Hong, Y.; Li, Y.; Hu, C.; Yip, T.-C.; Yu, W.-K.; Zhu, Y.; Fong, C.-C.; Wang, W.; Au, S.-K.; et al. Targeted destruction of cancer stem cells using multifunctional magnetic nanoparticles that enable combined hyperthermia and chemotherapy. Theranostics 2020, 10, 1181, doi:10.7150/thno.38989.

70. Wang, S.; Jiang, J.; Liang, X.; Tang, Y. Links between cancer stem cells and epithelial–mesenchymal transition. Onco. Targets. Ther. 2015, 8, 2973, doi:10.2147/OTT.S91863.

71. Duan, H.; Liu, Y.; Gao, Z.; Huang, W. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm. Sin. B 2021, 11, 55–70, doi:10.1016/j.apsb.2020.09.016.

72. Chiou, G.Y.; Cherng, J.Y.; Hsu, H.S.; Wang, M.L.; Tsai, C.M.; Lu, K.H.; Chien, Y.; Hung, S.C.; Chen, Y.W.; Wong, C.I.; et al. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation.
and cancer stem-like properties and in lung adenocarcinoma. J. Control. Release 2012, 159, 240–250, doi:10.1016/j.jconrel.2012.01.014.

73. N., K.; R. R.; S. V. The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung. Transl. lung Cancer Res. 2013, 2, 172–179, doi:10.9798/ISSN.2218-6751.2013.01.01.

74. Andey, T.; Bora-Singhal, N.; Chellappan, S.P.; Singh, M. Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors. Nanomedicine Nanotechnology. Biol. Med. 2019, 18, 31–43, doi:10.1016/j.nano.2019.02.007.

75. Di Nicolantonio, F.; Mercer, S.J.; Knight, L.A.; Gabriel, F.G.; Whitehouse, P.A.; Sharma, S.; Fernando, A.; Graysher, S.; Di Palma, S.; Johnson, P.; et al. Cancer cell adaptation to chemotherapy. BMC Cancer 2005, 5, 78, doi:10.1186/1471-2407-5-78.

76. Satta, T.; Isobe, K.-I; Yamauchi, M.; Nakashima, I.; Takagi, H. Expression of MDR1 and glutathione S-transferase-π genes and chemosensitivities in human gastrointestinal cancer. Cancer 1992, 69, 941–946, doi:10.1002/1097-0142(19920215)69:4<941::AID-CNCR2826904183.0.CO;2-H.

77. Guengerich, F.P. Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 2008, 21, 70–83, doi:10.1021/tx700079z.

78. Jancova, P.; Anzenbacher, P.; Anzenbacherova, E. Phase II drug metabolizing enzymes. Biomed. Pap. 2010, 154, 103–116, doi:10.5307/bp.2010.017.

79. Iyangan, T. Molecular Mechanism of Phase I and Phase II Drug-Metabolizing Enzymes: Implications for Detoxification. Int. Rev. Cytol. 2007, 260, 35–112, doi:10.1016/S0074-7696(06)60002-8.

80. Patel, M.; Taskar, K.S.; Zamek-Gliszczynski, M.J. Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites. J. Clin. Pharmacol. 2016, 56, S23–S39, doi:10.1002/jcph.671.

81. Sau, A.; Pellizzari Tregno, F.; Valentino, F.; Federici, G.; Caccuri, A.M. Gluthathione transferases and development of new principles to overcome drug resistance. Arch. Biochem. Biophys. 2010, 500, 116–122, doi:10.1016/j.abb.2010.05.012.

82. Tew, K.D.; Gäté, L. Glutathione S-transfases as emerging therapeutic targets. Expert Opin. Ther. Targets 2001, 5, 477–489, doi:10.1517/14728222.5.4.477.

83. Chen, C.S.; Lin, J.T.; Goss, K.A.; He, Y.A.; Halpert, J.R.; Waxman, D.J. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: Identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol. Pharmacol. 2004, 65, 1278–1285, doi:10.1124/mol.65.5.1278.

84. Kopeček, J.; Kopečková, P. %J. A. drug delivery reviews HPMA copolymers: origins, early developments, present, and future. 2010, 62, 122–149.

85. Brozovic, A.; Ambriović-Ristov, A.; Osmak, M. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit. Rev. Toxicol. 2010, 40, 347–359, doi:10.3109/1040844103601836.

86. Allocati, N.; Masulli, M.; Di Ilio, C.; Federici, L. Glutathione transferases: Substrates, inhibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis 2018, 7, 1–15, doi:10.1038/s41389-017-0025-3.

87. Ma, L.; Xu, Y.; Su, J.; Yu, H.; Kang, J.; Li, H.; Li, X.; Xie, Q.; Yu, C.; Sun, L.; et al. Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function. Int. J. Oncol. 2015, 47, 1890–1900, doi:10.3892/ijo.2015.3176.

88. Aoyama, K.; Nakaki, T. Impaired glutathione synthesis in neurodegeneration. Int. J. Mol. Sci. 2013, 14, 21021–21044, doi:10.3390/ijms141021021.

89. Awasthi, Y.C.; Singh, S.V.; Ahmad, H.; Moller, P.C. Immunocytochemical evidence for the expression of GST1, GST2, and GST3 gene loci for glutathione S-transferase in human lung. Lung 1987, 165, 323–332, doi:10.1007/BF02714448.

90. Ilio, C.; Di Boccio, G.; Del Aceto, G.; Casaccia, R.; McNally, F.; Federici, G. Elevation of glutathione transferase activity in human lung tumor. Carcinogenesis 1988, 9, 335–340, doi:10.1007/BF00366069.

91. Chen, H.H.W.; Kuo, M.T. %J. M. drugs Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. 2010, 2010.

92. Galluzzi, L.; Kepp, O.; Heiden, M.G.V.; Kroemer, G. Metabolic targets for cancer therapy. Nat. Rev. Drug Discov. 2013, 12, 829–846, doi:10.1038/nrd4145.

93. Yi, T.; Cho, S.G.; Yi, Z.; Pang, X.; Rodriguez, M.; Wang, Y.; Sethi, G.; Aggarwal, B.B.; Liu, M. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol. Cancer Ther. 2008, 7, 1789–1796, doi:10.1158/1535-7163.MCT-08-0124.

94. Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31, 1869–1883, doi:10.1038/onc.2011.384.

95. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: The multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295–1302, doi:10.1093/jnci/92.16.1295.

96. Wangpakitch, M.; Wu, C.; Li, Y.Y.; Nguyen, D.J.M.; Kim, M.; Chen, S.; Feun, L.G.; Prince, J.S.; Kuo, M.T.; et al. Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer. Oncotarget 2017, 8, 49275–49292, doi:10.18632/oncotarget.17568.

97. Damia, G.; D’Incalci, M. Mechanisms of resistance to alkylating agents. Cytotechnology 1998, 27, 165–173, doi:10.1007/s10614-017-2374-9-10.

98. Liu, Y.; Li, Q.; Zhou, L.; Xie, N.; Nice, E.C.; Zhang, H.; Huang, C.; Lei, Y. Cancer drug resistance: Redox resetting renders a way. Oncotarget 2016, 7, 42740–42761, doi:10.18632/oncotarget.8600.

99. Shanker, M.; Willcutts, D.; Roth, J.A.; Ramesh, R. Drug resistance in lung cancer. Lung Cancer Targets Ther. 2010, 1, 23–36, doi:10.2147/lett.s6861.

100. Moreira, A.F.; Dias, D.R.; Correia, I.J. Stimuli-responsive mesoporous silica nanoparticles for cancer therapy: A review. Microporous Mesoporous Mater. 2016, 236, 141–157, doi:10.1016/j.micromeso.2016.08.038.
101. Wang, J.; Sun, X.; Mao, W.; Sun, W.; Tang, J.; Sui, M.; Shen, Y.; Gu, Z. Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy. Adv. Mater. 2013, 25, 3670–3676, doi:10.1002/adma.201300929.

102. Wang, K.; Hu, Q.; Zhu, W.; Zhao, M.; Ping, Y.; Tang, G. Structure-invertible nanoparticles for triggered co-delivery of nucleic acids and hydrophobic drugs for combination cancer therapy. Adv. Funct. Mater. 2015, 25, 3380–3392, doi:10.1002/adfm.201403921.

103. Hu, Y.W.; Du, Y.Z.; Liu, N.; Liu, X.; Meng, T.T.; Cheng, B.L.; He, J.B.; You, J.; Yuan, H.; Hu, F.Q. Selective redox-responsive drug release in tumor cells mediated by chitosan based glycolipid-like nanocarrier. J. Control. Release 2015, 206, 91–100, doi:10.1016/j.jconrel.2015.03.018.

104. Zhang, W.; Lin, W.; Pei, Q.; Hu, X.; Xie, Z.; Jing, X. Redox-Hypersensitive Organic Nanoparticles for Selective Treatment of Cancer Cells. Chem. Mater. 2016, 28, 4440–4446, doi:10.1021/acs.chemmater.6b06141.

105. Stephen, Z.R.; Kievit, F.M.; Veiseh, O.; Chiarelli, P.A.; Fang, C.; Wang, K.; Hatzinger, S.J.; Ellenbogen, R.G.; Silber, J.R.; Zhang, M. Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O 6 -benzylguanine to brain tumors. ACS Nano 2014, 8, 10383–10395, doi:10.1021/nn503735w.

106. Qu, Q.; Wang, Y.; Zhang, L.; Zhang, X.; Zhou, S. A Nanoplatform with Precise Control over Release of Cargo for Enhanced Cancer Therapy. Small 2016, 12, 1378–1390, doi:10.1002/smll.201503292.

107. Xu, P.; Yu, H.; Zhang, Z.; Meng, Q.; Sun, H.; Chen, X.; Yin, Q.; Li, Y. Hydrogen-bonded and reduction-responsive micelles loading atorvastatin for therapy of breast cancer metastasis. Biomaterials 2014, 35, 7575–7587, doi:10.1016/j.biomaterials.2014.05.030.

108. Nguyen, C.T.; Tran, T.H.; Amiji, M.; Lu, X.; Kasi, R.M. Redox-sensitive nanoparticles from amphiphilic cholesterol-based block copolymers for enhanced tumor intracellular release of doxorubicin. Nanomedicine Nanotechnology, Biol. Med. 2015, 11, 2071–2082, doi:10.1016/j.nano.2015.06.011.

109. Hu, K.; Zhou, H.; Liu, Y.; Liu, Z.; Liu, J.; Tang, J.; Li, J.; Zhang, J.; Sheng, W.; Zhao, Y.; et al. Hyaluronic acid functional amphipathic-redox-responsive polymer particles for the co-delivery of doxorubicin and cyclosporine to eradicate breast cancer cells and cancer stem cells. Nanoscale 2015, 7, 8607–8618, doi:10.1039/c5nr01084e.

110. Park, H.K.; Lee, S.J.; Oh, J.S.; Lee, S.G.; Jeong, Y.I.L.; Lee, H.C. Smart Nanoparticles Based on Hyaluronic Acid for Redox-Responsive and CD44 Receptor-Mediated Targeting of Tumor. Nanoscale Res. Lett. 2015, 10, 1–10, doi:10.1186/s11671-015-0981-5.

111. Luo, Z.; Hu, Y.; Cai, K.; Ding, X.; Zhang, Q.; Li, M.; Ma, X.; Zhang, B.; Zeng, Y.; Li, P.; et al. Intracellular redox-activated anti-cancer drug delivery by functionalized hollow mesoporous silica nanoreservoirs with tumor specificity. Biomaterials 2014, 35, 7951–7962, doi:10.1016/j.biomaterials.2014.05.058.

112. Zhang, B.; Luo, Z.; Liu, J.; Ding, X.; Li, J.; Cai, K. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triple therapy in vitro and in vivo. J. Control. Release 2014, 192, 192–201, doi:10.1016/j.jconrel.2014.06.037.

113. Wang, H.; Li, Y.; Zhang, M.; Wu, D.; Shen, Y.; Tang, G.; Ping, Y. Redox-Activatable ATP-Depleting Micelles with Dual Modulation Characteristics for Multidrug-Resistant Cancer Therapy. Adv. Healthc. Mater. 2017, 6, 1601293, doi:10.1002/adhm.201601293.

114. Wang, X.; Cai, X.; Hu, J.; Shao, N.; Wang, F.; Zhang, Q.; Xiao, J.; Cheng, Y. Glutathione-triggered “off-On” release of anticancer drugs from dendrimer-encapsulated gold nanoparticles. J. Am. Chem. Soc. 2013, 135, 9805–9810, doi:10.1021/ja402903h.

115. Galluzzi, L.; Vitale, I.; Aaronson, S.A.; Abrams, D.; Adam, D.; Agostinis, P.; Alnemri, E.S.; Altucci, L.; Amelio, I.; Andrews, D.W.; et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018, 25, 486–541, doi:10.1038/s44148-017-0012-4.

116. Julien, O.; Wells, J.A. Caspases and their substrates. Cell Death Differ. 2017, 24, 1380–1389, doi:10.1038/cdd.2017.44.

117. Mohammad, R.M.; Muqbil, I.; Lowe, L.; Yedjou, C.; Hsu, H.Y.; Lin, L.T.; Siegelin, M.D.; Fimognari, C.; Kumar, N.B.; Dou, Q.P.; et al. Broad targeting of resistance to apoptosis in cancer. Semin. Cancer Biol. 2015, 35, S78–S103, doi:10.1016/j.semcancer.2015.03.001.

118. Balaji, S.; Terrero, D.; Tiwari, A.K.; Ashby, C.R.; Raman, D. Alternative approaches to overcome chemoresistance to apoptosis in cancer. Adv. Protein Chem. Struct. Biol. 2021, 126, 91–122, doi:10.1002/9781119699663.pdf.

119. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674, doi:10.1016/j.cell.2011.02.013.

120. Igney, F.H.; Krammer, P.H. Death and anti-death: Tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2, 277–288, doi:10.1038/nrc776.

121. Czabotar, P.E.; Lee, E.F.; Thompson, G. V.; Wardak, A.Z.; Fairlie, W.D.; Colman, P.M. Mutation to bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis. J. Biol. Chem. 2011, 286, 7123–7131, doi:10.1074/jbc.M110.161281.

122. Le Gallo, M.; Poissonnier, A.; Blanco, P.; Legembre, P. CD95/Fas, non-apoptotic signaling pathways, and kinases. Front. Immunol. 2017, 8, doi:10.3389/fimmu.2017.01216.

123. Yuan, X.J.; Whang, Y.E. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 2002, 21, 319–327, doi:10.1038/sj.onc.1205054.

124. Fulda, S.; Vucic, D. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 2012, 11, 109–124, doi:10.1038/nrd3627.

125. Rathore, R.; McCallum, J.E.; Varghese, E.; Florea, A.M.; Büsselberg, D. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis 2017, 22, 898–919, doi:10.1007/s10495-017-1375-1.

126. Yang, D.; Chen, M. Bin; Wang, L.Q.; Yang, L.; Liu, C.Y.; Lu, P.H. Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: A systematic review and meta-analysis. J. Exp. Clin. Cancer Res. 2013, 32, 105, doi:10.1186/1756-9966-32-105.
127. Zhang, J.; Wang, S.; Wang, L.; Wang, R.; Chen, S.; Pan, B.; Sun, Y.; Chen, H. Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: A meta-analysis and systemic review. Onco. Targets. Ther. 2015, 8, 3361–3369, doi:10.2147/OTT.S89275.

128. Sjöström, J.; Von Boguschlawski, K.; Saksela, E.; Blomqvist, C.; Bengtsson, N.O.; Malmström, P.; Mjaaland, I.; Ostenstadt, B.; Wist, E.; Valvere, V.; et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin. Cancer Res. 2002, 8, 811–816.

129. Krug, L.M.; Miller, V.A.; Filippa, D.A.; Venkatraman, E.; Ng, K.K.; Kris, M.G. Bcl-2 and bax expression in advanced non-small cell lung cancer: Lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine. Lung Cancer 2003, 39, 139–143, doi:10.1016/s0169-5002(02)00443-8.

130. Shim, M.K.; Moon, Y.; Yang, S.; Kim, J.; Cho, H.; Lim, S.; Yoon, H.Y.; Seong, J.K.; Kim, K. Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy. Biomaterials 2020, 261, 120347, doi:10.1016/j.biomaterials.2020.120347.

131. Wang, H.; Zhang, F.; Wen, H.; Shi, W.; Huang, Q.; Huang, Y.; Xie, J.; Li, P.; Chen, J.; Qin, L.; et al. Tumor- And mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis. J. Nanobiotechnology 2020, 18, 8, doi:10.1186/s12951-019-0562-3.

132. Marrache, S.; Pathak, R.K.; Dhar, S. Detouring of cisplatin to access mitochondrial genome for overcoming resistance. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 10444–10449, doi:10.1073/pnas.1405244111.

133. Yao, Y.; Zhou, Y.; Liu, L.; Xu, Y.; Chen, Q.; Wang, Y.; Wu, S.; Deng, Y.; Zhang, J.; Shao, A. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front. Mol. Biosci. 2020, 7, doi:10.3389/fmolb.2020.00193.

134. Choi, K.Y.; Correa, S.; Min, J.; Li, J.; Roy, S.; Lacciott, K.H.; Dreaden, E.; Kong, S.; Heo, R.; Roh, Y.H.; et al. Binary Targeting of siRNA to Hematologic Cancer Cells In Vivo Using Layer-by-Layer Nanoparticles. Adv. Funct. Mater. 2019, 29, 1900018, doi:10.1002/adfm.201900018.

135. Choi, S.H.; Jin, S.E.; Lee, M.K.; Lim, S.J.; Park, J.S.; Kim, B.G.; Ahn, W.S.; Kim, C.K. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur. J. Pharm. Biopharm. 2008, 68, 545–554, doi:10.1016/j.ejpb.2007.07.011.

136. Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; Sarkar, S. Drug resistance in cancer: an overview. 2014.

137. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. N. Engl. J. Med. 2004, 350, 2129–2139, doi:10.1056/nejmoa040938.

138. Turajlic, S.; Furney, S.J.; Stamp, G.; Rana, S.; Ricken, G.; Oduko, Y.; Saturno, G.; Springer, C.; Hayes, A.; Gore, M.; et al. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann. Oncol. 2014, 25, 959–967, doi:10.1093/annonc/mdu049.

139. Dearden, S.; Stevens, J.; Wu, Y.L.; Blowers, D. Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap). Ann. Oncol. 2013, 24, 2371–2376, doi:10.1093/annonc/mdt020.

140. Kim, S.; Kim, T.M.; Kim, D.W.; Go, H.; Keam, B.; Lee, S.H.; Ku, J.L.; Chung, D.H.; Heo, D.S. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J. Thorac. Oncol. 2013, 8, 415–422, doi:10.1097/JTO.0b013e318283dccc.

141. Mitiushkina, N. V.; Iyeleva, A.G.; Poltoratskiy, A.N.; Ivantsov, A.O.; Togo, A. V.; Polyakov, I.S.; Orlov, S. V.; Matsko, D.E.; Novik, V.I.; Iyevleva, A.G.; Poltoratskiy, A.N.; Ivantsov, A.O.; Togo, A. V.; Polyakov, I.S.; Orlov, S. V.; Matsko, D.E.; Novik, V.I.; Imyanitov, E.N. Detection of egfr mutations and eml4-alk rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol. 2013, 121, 370–376, doi:10.1002/cncr.21281.

142. Gainor, J.; Dardei, L.; Yoda, S.; Friboulet, L.; Leisich, I.; Katayama, R.; Dagogo-Jack, I.; Gadgeel, S.; Schultz, K.; Singh, M.; et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Eur. J. Cancer 2016, 69, S138, doi:10.1016/s0959-8049(16)33009-x.

143. Milella, M.; Falcone, I.; Conciatori, F.; Incan, U.C.; Del Curatolo, A.; Inzierilli, N.; Nuzzo, C.M.A.; Vaccaro, V.; Vari, S.; Cognetti, F.; et al. PTEN: Multiple functions in human malignant tumors. Front. Oncol. 2015, 5, 24, doi:10.3389/fonc.2015.00024.

144. Cantley, L.C.; Neel, B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 4240–4245, doi:10.1073/pnas.96.8.4240.

145. Sos, M.L.; Koker, M.; Weir, B.A.; Heynck, S.; Rabinovisky, R.; Zander, T.; Seeger, J.M.; Weiss, J.; Fischer, F.; Frommolt, P.; et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of akt and EGFR. Cancer Res. 2009, 69, 3256–3261, doi:10.1158/0008-5472.CAN-08-4055.

146. Niu, G.; Chen, X. C drug targets Vascular endothelial growth factor as an antiangiogenic target for cancer therapy. 2010, 11, 1000–1017.

147. Loges, S.; Schmidt, T.; Carmeliet, P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes and Cancer 2010, 1, 12–25, doi:10.1177/1947601909356574.

148. Kawakami, T.; Tokunaga, T.; Hatanaka, H.; Kijima, H.; Yamazaki, H.; Abe, Y.; Osamura, Y.; Inoue, H.; Ueyama, Y.; Nakamura, M. Neuritin 1 and neuritin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 2002, 95, 2196–2201, doi:10.1002/cncr.10936.

149. Gridelli, C.; de Marinis, F.; Ardizzoni, A.; Novello, S.; Fontanini, G.; Cappuzzo, F.; Grossi, F.; Santo, A.; Cortinovis, D.; Favareto, A.; et al. Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. J. Cancer Res. Clin. Oncol. 2014, 140, 1783–1793, doi:10.1007/s00432-014-1715-2.
150. Gridelli, C.; De Marinis, F.; Di Maio, M.; Cortinovis, D.; Cappuzzo, F.; Mok, T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues. Lung Cancer 2011, 72, 3–8, doi:10.1016/j.lungcan.2010.12.009.

151. Bell, D.W.; Gore, J.; Okimoto, R.A.; Godin-Heymann, N.; Sordella, R.; Mulloy, R.; Sharma, S. V.; Brannigan, B.W.; Mohapatra, G.; Settleman, J.; et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 2005, 37, 1315–1316, doi:10.1038/ng1671.

152. Tang, J.; Salama, R.; Gadgeel, S.M.; Sarkar, F.H.; Ahmad, A. Erlotinib resistance in lung cancer: Current progress and future perspectives. Front. Pharmacol. 2013, 4 FEB, 15, doi:10.3389/fphar.2013.00015.

153. Ma, C.; Wei, S.; Song, Y. T790M and acquired resistance of EGFR TKI: A literature review of clinical reports. J. Thorac. Dis. 2011, 3, 10–18, doi:10.3978/j.issn.2072-1439.2010.12.02.

154. Paez, J.G.; Jänne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; et al. EGFR mutations in lung cancer: Correlation with clinical response to gefinitin therapy. Science (80-. ). 2004, 304, 1497–1500, doi:10.1126/science.1099314.

155. Suda, K.; Onozato, R.; Yatabe, Y.; Mitsudomi, T. EGFR T790M mutation: A double role in lung cancer cell survival? J. Thorac. Oncol. 2009, 4, 1–4, doi:10.1097/JTO.0b013e3181913c9f.

156. Yasuda, H.; Park, E.; Yun, C.H.; Sng, N.J.; Lucena-Araujo, A.R.; Yeo, W.L.; Huberman, M.S.; Cohen, D.W.; Nakayama, S.; Ishioka, K.; et al. Structural, biochemical, and chemical characterization of Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in lung cancer (Science Translational Medicine (2014) 6, 225Ser1)). Sci. Transl. Med. 2014, 6, 216ra177–216ra177, doi:10.1126/scitranslmed.3008733.

157. Peng, H.; Chen, B.; Huang, W.; Tang, Y.; Jiang, Y.; Zhang, W.; Huang, Y. Reprogramming Tumor-Associated Macrophages to Reverse EGFR/T790M Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat. Nano Lett. 2017, 17, 7684–7690, doi:10.1021/acs.nanolett.7b03756.

158. Yin, W.; Yu, X.; Kang, X.; Zhao, Y.; Zhao, P.; Jin, H.; Fu, X.; Yan, W.; Peng, C.; Huang, Y. Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFR/T790M-Associated Drug Resistance by PD-L1 Nanobody-Mediated Codelivery. Small 2018, 14, 1802372, doi:10.1002/smll.201802372.

159. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8, 193–204, doi:10.1038/nrc2342.

160. Gillet, J.P.; Gottesman, M.M. Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 2010; Vol. 596, pp. 47–76.

161. Ullsdemolins, A.; Seras-Franzos, J.; Andrade, F.; Rafael, D.; Abasolo, I.; Gener, P.; Schwartz, S. Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. Cancer Drug Resist. 2021, 4, 44–68, doi:10.20517/cdr.2020.59.

162. Desai, A.; Yan, Y.; Gerson, S.L. Advances in therapeutic targeting of the DNA damage response in cancer. DNA Repair (Amst.) 2018, 66, 24–29, doi:10.1016/j.dnarep.2018.04.004.

163. Rocha, C.R.R.; Silva, M.M.; Quinet, A.; Cabral-Neto, J.B.; Menck, C.F.M. DNA repair pathways and cisplatin resistance: An intimate relationship. Clinics 2018, 73, doi:10.6061/clinics/2018/e478s.

164. Yu, W.K.; Wang, Z.; Fong, C.C.; Liu, D.; Yip, T.C.; Au, S.K.; Zhu, G.; Yang, M. Chemoresistant lung cancer stem cells display high DNA repair capability to remove cisplatin-induced DNA damage. Br. J. Pharmacol. 2017, 174, 302–313, doi:10.1111/bph.13690.

165. Olausen, K.A.; Dunant, A.; Fouret, P.; Brambilla, E.; André, F.; Haddad, V.; Taranchon, E.; André, F.; Pirker, R.; Popper, H.H.; et al. DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. N. Engl. J. Med. 2006, 355, 983–991, doi:10.1056/nejmoa060570.

166. Tell, G.; Damante, G.; Caldwell, D.; Kelley, M.R. The intracellular localization of APE1/Ref-1: More than a passive phenomenon? Antioxidants Redox Signal. 2005, 7, 367–384, doi:10.1089/ars.2005.7.367.

167. Huang, R.; Zhou, P.K. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct. Target. Ther. 2021, 6, 254, doi:10.1038/s41392-021-00648-7.

168. Chen, P.; Li, J.; Jiang, H.G.; Lan, T.; Chen, Y.C. Curcumin reverses cisplatin resistance in cisplatin-resistant lung cancer cell targets by inhibating FA/BRCRA pathway. Tumor Biol. 2015, 36, 3591–3599, doi:10.1007/s13277-014-2996-4.

169. Hong, Y.; Che, S.; Hui, B.; Wang, X.; Zhang, X.; Ma, H. Combination therapy of lung cancer using layer-by-layer cisplatin prodrug and curcumin co-encapsulated nanomedicine. Drug Des. Devel. Ther. 2020, 14, 2263–2274, doi:10.2147/DDDT.S241291.

170. Kong, Y.W.; Dreden, E.C.; Morandell, S.; Zhou, W.; Dhara, S.S.; Sriram, G.; Lam, F.C.; Patterson, J.C.; Quadril, M.; Dinh, A.; et al. Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints. Nat. Commun. 2020, 11, 4124, doi:10.1038/s41467-020-17958-z.

171. Chen, Y.Y.; Lin, Y.J.; Huang, W.T.; Hung, C.C.; Lin, H.Y.; Tu, Y.C.; Liu, D.M.; Lan, S.J.; Sheu, M.J. Demethoxycurcumin-loaded chitosan nanoparticle downregulates DNA repair pathway to improve cisplatin-induced apoptosis in non-small cell lung cancer. Molecules 2018, 23, 3217, doi:10.3390/molecules23123217.

172. Godin-Heymann, N.; Ulkus, L.; Brannigan, B.W.; McDermott, U.; Lamb, J.; Maheswaran, S.; Settleman, J.; Haber, D.A. The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol. Cancer Ther. 2008, 7, 874–879, doi:10.1158/1535-7163.MCT-07-2387.

173. Sequist, L. V.; Wallman, B.A.; Dias-Santagata, D.; Digumarthy, S.; Turke, A.B.; Fidias, P.; Bergheton, K.; Shaw, A.T.; Gettinger, S.; Cosper, A.K.; et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3, 75ra26-75ra26, doi:10.1126/scitranslmed.3002003.
Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Joon, O.P.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.; et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (80-.). 2007, 316, 1039–1043, doi:10.1126/science.1141478.

Turke, A.B.; Zejnullahu, K.; Wu, Y.L.; Song, Y.; Dias-Santagata, D.; Lišňátková, T.; Soschick, L.; Rogers, A.; Mok, T.; Sequist, L.; et al. Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC. Cancer Cell 2010, 17, 77–88, doi:10.1016/j.ccr.2009.11.022.

Sattler, M.; Reddy, M.M.; Hasina, R.; Gangadhar, T.; Salgia, R. The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther. Adv. Med. Oncol. 2011, 3, 171–184, doi:10.1177/1758834011408636.

Shi, P.; Oh, Y.T.; Zhang, G.; Yao, W.; Yue, P.; Li, Y.; Kanteti, R.; Riehm, J.; Salgia, R.; Owonikoko, T.K.; et al. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and second generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016, 380, 494–504, doi:10.1016/j.canlet.2016.07.021.

Le, X.; Puri, S.;Negro, M. V.; Nilsson, M.B.; Robichaux, J.; Boyle, T.; Kevin Hicks, J.; Lovering, K.L.; Roarty, E.; Rinsurongkawong, W.; et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin. Cancer Res. 2018, 24, 6195–6203, doi:10.1158/1078-0432.CCR-18-1542.

Yabuki, N.; Sakata, K.; Yamasaki, T.; Terashima, H.; Mio, T.; Miyazaki, Y.; Fujii, T.; Kitada, K. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet. Cytogenet. 2007, 173, 1–9, doi:10.1016/j.crcancer.2006.07.020.

Chen, C.; Jie, Chin, J.E.; Ueda, K.; Clark, D.P.; Pastan, I.; Gottesman, M.M.; Roninson, I.B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47, 381–389, doi:10.1016/0008-8864(86)90395-7.

Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48–58, doi:10.1038/nrc7076.

Saad, M.; Garbuzev, O.B.; Minko, T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine 2008, 3, 761–776, doi:10.2217/17435889.3.6.761.

Zhu, B.; Reining, D. Epigenetic inheritance: Uncontested? Cell Res. 2011, 21, 435–441, doi:10.1038/cr.2011.26.

Robert, A.; Valdes, A.F.; Torrellas, R.; Fraga, M.F.; Fernandez, A.F. Epigenetics in cancer therapy and nanomedicine. Clin. Epigenetics 2019, 11, 81, doi:10.1186/s13148-019-0675-4.

Cheng, Y.; He, C.; Wang, M.; Ma, X.; Mo, F.; Yang, S.; Han, J.; Wei, X. Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduct. Target. Ther. 2019, 4, 62, doi:10.1038/s41392-019-0095-0.

Witting, R.H.; Dannenberg, J.H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist. Update. 2012, 15, 21–38, doi:https://doi.org/10.1016/j.drup.2012.01.008.

Glozak, M.A.; Seto, E. Histone deacetylases and cancer. Oncogene 2007, 26, 5420–5432, doi:10.1038/sj.onc.1210610.

Mamdani, H.; Jalal, S.I. Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope? Front. Cell Dev. Biol. 2020, 8, doi:10.3389/fcell.2020.582370.

Wang, L.; Li, H.; Ren, Y.; Zhou, S.; Fang, W.; Jiang, X.; Jia, L.; Li, M.; Liu, X.; Yuan, X.; et al. Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms. Cell Death Dis. 2016, 7, e2063–e2063, doi:10.1038/cddis.2015.328.

Sharma, S. V.; Lee, D.Y.I.; Li, B.; Quinlan, M.P.; Takahashi, F.; Maheswaran, S.; McDermott, U.; Azizian, N.; Zou, L.; Fischbach, M.A.; et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations. Cell 2010, 141, 69–80, doi:10.1016/j.cell.2010.02.027.

Wang, E.C.; Min, Y.; Palm, R.C.; Fiordalisi, J.J.; Wagner, K.T.; Hyder, N.; Cox, A.D.; Caster, J.M.; Tian, X.; Wang, A.Z. Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. Biomaterials 2015, 51, 208–215, doi:10.1016/j.biomaterials.2015.02.015.

Tran, T.H.; Ramasamy, T.; Truong, D.H.; Shin, B.S.; Choi, H.G.; Yong, C.S.; Kim, J.O. Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Pharm. Res. 2014, 31, 1978–1988, doi:10.1007/s11095-014-1300-z.

Tu, B.; Zhang, M.; Liu, T.; Huang, Y. Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy. Front. Cell Dev. Biol. 2020, 8, doi:10.3389/fcell.2020.582370.

Cho, M.H.; Choi, E.S.; Kim, S.; Goh, S.H.; Choi, Y. Redox-responsive manganese dioxide nanoparticles for enhanced MR imaging and radiotherapy of lung cancer. Front. Chem. 2017, 5, 109, doi:10.3389/fchem.2017.00109.

Jiang, T.; Sun, W.; Zhu, Q.; Burns, N.A.; Khan, S.A.; Mo, R.; Gu, Z. Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene. Adv. Mater. 2015, 27, 1021–1028, doi:10.1002/adma.201404498.

Lam, A.T.N.; Yoon, J.; Gangold, E.O.; Singh, D.K.; Kim, D.; Cho, K.H.; Lee, S.Y.; Choo, J.; Lee, K.; Joo, S.W. Colloidal gold nanoparticle conjugates of gefitinib. Colloids Surfaces B Biointerfaces 2014, 123, 61–67, doi:10.1016/j.colsurfb.2014.08.021.

Lam, A.T.N.; Yoon, J.; Gangold, E.O.; Singh, D.K.; Kim, D.; Cho, K.H.; Son, S.J.; Choo, J.; Lee, S.Y.; Kim, S.; et al. Adsorption and desorption of tyrosine kinase inhibitor erlotinib on gold nanoparticles. J. Colloid Interface Sci. 2014, 425, 96–101, doi:10.1016/j.jcis.2014.03.032.

Morton, S.W.; Lee, M.J.; Deng, Z.J.; Dreaden, E.C.; Siouave, E.; Shopowitz, K.E.; Shah, N.J.; Yaffe, M.B.; Hammond, P.T. A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci. Signal. 2014, 7, ra44–ra44, doi:10.1126/scisignal.2005261.
199. Li, N.; Zhang, C.X.; Wang, X.X.; Zhang, L.; Ma, X.; Zhou, J.; Ju, R.J.; Li, X.Y.; Zhao, W.Y.; Lu, W.L. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways. Biomaterials 2013, 34, 3366–3380, doi:10.1016/j.biomaterials.2013.01.055.

200. Guo, L.; Fan, L.; Pang, Z.; Ren, J.; Ren, Y.; Li, J.; Chen, J.; Wen, Z.; Jiang, X. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J. Control. Release 2011, 154, 93–102, doi:10.1016/j.jconrel.2011.05.008.

201. Zhang, X.; Yang, H.; Gu, K.; Chen, J.; Rui, M.; Jiang, G.L. In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer. Int. J. Nanomedicine 2011, 6, 437–444, doi:10.2147/ijn.s19997.

202. Zhang, Y.; Peng, L.; Mumper, R.J.; Huang, L. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials 2013, 34, 8459–8468, doi:10.1016/j.biomaterials.2013.07.050.

203. Zhang, Y.; Schwerbrock, N.M.J.; Rogers, A.B.; Kim, W.Y.; Huang, L. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol. Ther. 2013, 21, 1559–1569, doi:10.1038/mt.2013.120.

204. Wang, B.L.; Shen, Y.M.; Zhang, Q.W.; Li, Y.L.; Luo, M.; Liu, Z.; Li, Y.; Qian, Z.Y.; Gao, X.; Shi, H.S. Codelivery of curcumin and doxorubicin by MPEG-PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancer. Int. J. Nanomedicine 2013, 8, 3521–3531, doi:10.2147/ijn.s45250.

205. Shen, J.; Yin, Q.; Chen, L.; Zhang, Z.; Li, Y. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 2012, 33, 8613–8624, doi:10.1016/j.biomaterials.2012.08.007.

206. Han, W.; Shi, L.; Ren, L.; Zhou, L.; Li, T.; Qiao, Y.; Wang, H. A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer. Signal Transduct. Target. Ther. 2018, 3, 1–10, doi:10.1038/s41392-018-0019-4.

207. Wang, D.; Tang, J.; Wang, Y.; Ramishetti, S.; Fu, Q.; Racette, K.; Liu, F. Multifunctional nanoparticles based on a single-molecule modification for the treatment of drug-resistant cancer. Mol. Pharm. 2013, 10, 1465–1469, doi:10.1021/mp400022h.

208. Yang, C.; Yong; Wang, L.; Sun, X.; Tang, M.; Quan, H.; Tian; Zhang, L.; Shan; Lou, L.; Gu; S.; Hua SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models. Acta Pharmacol. Sin. 2019, 40, 971–979, doi:10.1038/s41401-018-0198-0.

209. Green, M.R.; Manikhas, G.M.; Orlov, S.; Afanasyev, B.; Makhson, A.M.; Bhar, P.; Hawkins, M.J. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2006, 17, 1263–1268, doi:10.1093/annonc/dml104.

210. Arms, L.; Smith, D.W.; Flynn, J.; Palmer, W.; Martin, A.; Woldu, A.; Hua, S. Advantages and limitations of current techniques for analyzing the biodistribution of nanoparticles. Front. Pharmacol. 2018, 9, doi:10.3389/fphar.2018.00802.

211. Anselmo, A.C.; Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl. Med. 2016, 1, 10–29, doi:10.1002/btm2.10003.

212. Kolb, H.C.; Finn, M.G.; Sharpless, K.B. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew. Chemie Int. Ed. 2001, 40, 2004–2007, doi:10.1002/1521-3773(20010601)40:11<2004::AID-Anie2004>3.3.co;2-x.

213. Lallana, E.; Sousa-Heraves, A.; Fernandez-Trillo, F.; Rigüera, R.; Fernandez-Megia, E. Click chemistry for drug delivery nanosystems. Pharm. Res. 2012, 29, 1–34, doi:10.1007/s11095-011-0568-5.

214. Shoba, G.; Joy, D.; Joseph, T.; Majeed, M.; Rajendran, R.; Srinivas, P.S.S.R. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998, 64, 353–356, doi:10.1055/s-2006-957450.

215. Cheng, Z.; Al Zaki, A.; Hui, J.Z.; Muzykantov, V.R.; Tsourkas, A. Multifunctional nanoparticles: Cost versus benefit of adding targeting and imaging capabilities. Science (80-. ). 2012, 338, 903–910, doi:10.1126/science.1226338.

216. Fleck, L.M. The Costs of Caring: Who Pays? Who Profits? Who Panders? Hastings Cent. Rep. 2006, 36, 13–17, doi:10.1353/hcr.2006.0040.

217. Desai, N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012, 14, 282–295, doi:10.1208/s12248-012-9339-4.

218. Alexiou, C.; Schmid, R.J.; Jurgons, R.; Kremer, M.; Wanner, G.; Bergemann, C.; Huenges, E.; Nawroth, T.; Arnold, W.; Parak, F.G. Targeting cancer cells: Magnetic nanoparticles as drug carriers. Eur. Biophys. J. 2006, 35, 446–450, doi:10.1007/s00249-006-0042-1.

219. Chatterjee, D.K.; Fong, L.S.; Zhang, Y. Nanoparticles in photodynamic therapy: An emerging paradigm. Adv. Drug Deliv. Rev. 2008, 60, 1627–1637, doi:10.1016/j.addr.2008.08.003.

220. Luo, M.; Li, H.; Han, D.; Yang, K.; Kang, L. Inhibition of Autophagy Enhances Apoptosis Induced by Ce6-Photodynamic Therapy in Human Colon Cancer Cells. Photodiagnostics Photodyn. Ther. 2021, 36, 102605, doi:10.1016/j.pdpdt.2021.102605.

221. Deng, X.; Song, Q.; Zhang, Y.; Liu, W.; Hu, H.; Zhang, Y. Tumor microenvironment-responsive nanoplatform based on biodegradable liposome-coated hollow MnO2 for synergistically enhanced chemotherapy and photodynamic therapy. J. Drug Target. 2021, 1, 23, doi:10.1080/1061186x.2021.1999961.

222. Crous, A.; Abrahamse, H. Aluminium (III) phthalocyanine chloride tetrasulfonate is an effective photosensitizer for the eradication of lung cancer stem cells. R. Soc. Open Sci. 2021, 8, 210148, doi:10.1098/rsos.210148.

223. Yu, T.T.; Sang, X.Y.; Han, N.; Peng, X.C.; Li, Q.R.; Xu, X.; Xiao, R.C.; Xu, H.Z.; Chen, X.; Wang, M.F.; et al. Macrophages mediated delivery of chlorin e6 and treatment of lung cancer by photodynamic reprogramming. Int. Immunopharmacol. 2021, 100, 108164, doi:10.1016/j.intimp.2021.108164.
224. Shi, C.; Huang, H.; Zhou, X.; Zhang, Z.; Ma, H.; Yao, Q.; Shao, K.; Sun, W.; Du, J.; Fan, J.; et al. Reversing Multidrug Resistance by Inducing Mitochondrial Dysfunction for Enhanced Chemo-Photodynamic Therapy in Tumor. ACS Appl. Mater. Interfaces 2021, 13, 45259–45268, doi:10.1021/acsami.1c12725.

225. Reshma, P.L.; Unnikrishnan, B.S.; Preethi, G.U.; Syama, H.P.; Archana, M.G.; Remya, K.; Shiji, R.; Sreekutty, J.; Sreelekha, T.T. Overcoming drug-resistance in lung cancer cells by paclitaxel loaded galactoxyloglucan nanoparticles. Int. J. Biol. Macromol. 2019, 136, 266–274, doi:10.1016/j.ijbiomac.2019.06.075.